Podcasts about Endocrinology

A memoir of a child's forced relocation to Siberia under Stalin's Gulag system reveals the potential for true human kindness in the face of extraordinary hardship.  In April of 1940, six-year-old Ida woke to the sound of pounding on her door. Soviet soldiers forcibly packed her and her mother onto a train with thousands of their neighbors and deported them to remote Siberia, leaving them stranded to survive the brutal winter in subhuman conditions. Looking back, Ida shares their struggles: foraging for food, trying to reunite with her imprisoned father, spending weeks in a desolate hospital with typhoid fever, and adapting to shifts in the political climate to make the long journey home to Poland. Ida published this acclaimed memoir in her native Polish in 2011. Here, Ida's granddaughter, Isabella Skrypczak, translates her babcia's words and provides additional context—including describing the remarkable life Ida has gone on to live as a pioneering doctor. In the vein of Anne Frank's The Diary of a Young Girl, A Polish Girl in Siberia: Surviving and Transcending Exile (Disruption Books, 2026) chronicles Ida's experiences on a lesser-known front of the Second World War. Together, Ida and Isabella reflect on how every small act of kindness contributed to Ida's liberation from exile and ability to build a life and a family. Her story celebrates the capacity of the human spirit to not only survive trauma but thrive beyond it.Ida Kinalska-Pietruska survived childhood exile to Siberia during the Soviet Union's World War II assault on Poland. When she returned to Poland as a teen, she began studying medicine. A pioneering endocrinologist, she founded the School of Endocrinology and Diabetology in Białystok and led the region's first endocrinology clinic for twenty years. Ida has authored more than four hundred publications, mentored countless other doctors, and collaborated across the international medical community, including using her research to make widely known the Chernobyl disaster's effects on people's endocrinological health. She has been honored with the Order Odrodzenia Polski, Poland's second-highest civilian state award, and two Doctor Honoris Causa titles, reflecting her resilience, brilliance, and global impact on science and humanity.Isabella Skrypczak is an author, intuitive healer, and former HR professional in Big Tech whose work bridges the seen and unseen. Born to Polish immigrants and raised in Houston, Texas, she spent every summer with her grandmother in Poland. When her grandmother's memoir gained national attention in Polish media, Iza felt called to translate it into English—an act of love, remembrance, and advocacy. As war returned to Eastern Europe, she recognized the urgency in sharing this history with the Western world. She lives in Austin, Texas, with her daughter, Kamila.Stephen Satkiewicz is an independent scholar with research areas spanning Civilizational Sciences, Social Complexity, Big History, Historical Sociology, Military History, War Studies, International Relations, Geopolitics, and Russian and East European history. He is currently the Book Review Editor for Comparative Civilizations Review. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

A memoir of a child's forced relocation to Siberia under Stalin's Gulag system reveals the potential for true human kindness in the face of extraordinary hardship.  In April of 1940, six-year-old Ida woke to the sound of pounding on her door. Soviet soldiers forcibly packed her and her mother onto a train with thousands of their neighbors and deported them to remote Siberia, leaving them stranded to survive the brutal winter in subhuman conditions. Looking back, Ida shares their struggles: foraging for food, trying to reunite with her imprisoned father, spending weeks in a desolate hospital with typhoid fever, and adapting to shifts in the political climate to make the long journey home to Poland. Ida published this acclaimed memoir in her native Polish in 2011. Here, Ida's granddaughter, Isabella Skrypczak, translates her babcia's words and provides additional context—including describing the remarkable life Ida has gone on to live as a pioneering doctor. In the vein of Anne Frank's The Diary of a Young Girl, A Polish Girl in Siberia: Surviving and Transcending Exile (Disruption Books, 2026) chronicles Ida's experiences on a lesser-known front of the Second World War. Together, Ida and Isabella reflect on how every small act of kindness contributed to Ida's liberation from exile and ability to build a life and a family. Her story celebrates the capacity of the human spirit to not only survive trauma but thrive beyond it.Ida Kinalska-Pietruska survived childhood exile to Siberia during the Soviet Union's World War II assault on Poland. When she returned to Poland as a teen, she began studying medicine. A pioneering endocrinologist, she founded the School of Endocrinology and Diabetology in Białystok and led the region's first endocrinology clinic for twenty years. Ida has authored more than four hundred publications, mentored countless other doctors, and collaborated across the international medical community, including using her research to make widely known the Chernobyl disaster's effects on people's endocrinological health. She has been honored with the Order Odrodzenia Polski, Poland's second-highest civilian state award, and two Doctor Honoris Causa titles, reflecting her resilience, brilliance, and global impact on science and humanity.Isabella Skrypczak is an author, intuitive healer, and former HR professional in Big Tech whose work bridges the seen and unseen. Born to Polish immigrants and raised in Houston, Texas, she spent every summer with her grandmother in Poland. When her grandmother's memoir gained national attention in Polish media, Iza felt called to translate it into English—an act of love, remembrance, and advocacy. As war returned to Eastern Europe, she recognized the urgency in sharing this history with the Western world. She lives in Austin, Texas, with her daughter, Kamila.Stephen Satkiewicz is an independent scholar with research areas spanning Civilizational Sciences, Social Complexity, Big History, Historical Sociology, Military History, War Studies, International Relations, Geopolitics, and Russian and East European history. He is currently the Book Review Editor for Comparative Civilizations Review. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/russian-studies

A memoir of a child's forced relocation to Siberia under Stalin's Gulag system reveals the potential for true human kindness in the face of extraordinary hardship.  In April of 1940, six-year-old Ida woke to the sound of pounding on her door. Soviet soldiers forcibly packed her and her mother onto a train with thousands of their neighbors and deported them to remote Siberia, leaving them stranded to survive the brutal winter in subhuman conditions. Looking back, Ida shares their struggles: foraging for food, trying to reunite with her imprisoned father, spending weeks in a desolate hospital with typhoid fever, and adapting to shifts in the political climate to make the long journey home to Poland. Ida published this acclaimed memoir in her native Polish in 2011. Here, Ida's granddaughter, Isabella Skrypczak, translates her babcia's words and provides additional context—including describing the remarkable life Ida has gone on to live as a pioneering doctor. In the vein of Anne Frank's The Diary of a Young Girl, A Polish Girl in Siberia: Surviving and Transcending Exile (Disruption Books, 2026) chronicles Ida's experiences on a lesser-known front of the Second World War. Together, Ida and Isabella reflect on how every small act of kindness contributed to Ida's liberation from exile and ability to build a life and a family. Her story celebrates the capacity of the human spirit to not only survive trauma but thrive beyond it.Ida Kinalska-Pietruska survived childhood exile to Siberia during the Soviet Union's World War II assault on Poland. When she returned to Poland as a teen, she began studying medicine. A pioneering endocrinologist, she founded the School of Endocrinology and Diabetology in Białystok and led the region's first endocrinology clinic for twenty years. Ida has authored more than four hundred publications, mentored countless other doctors, and collaborated across the international medical community, including using her research to make widely known the Chernobyl disaster's effects on people's endocrinological health. She has been honored with the Order Odrodzenia Polski, Poland's second-highest civilian state award, and two Doctor Honoris Causa titles, reflecting her resilience, brilliance, and global impact on science and humanity.Isabella Skrypczak is an author, intuitive healer, and former HR professional in Big Tech whose work bridges the seen and unseen. Born to Polish immigrants and raised in Houston, Texas, she spent every summer with her grandmother in Poland. When her grandmother's memoir gained national attention in Polish media, Iza felt called to translate it into English—an act of love, remembrance, and advocacy. As war returned to Eastern Europe, she recognized the urgency in sharing this history with the Western world. She lives in Austin, Texas, with her daughter, Kamila.Stephen Satkiewicz is an independent scholar with research areas spanning Civilizational Sciences, Social Complexity, Big History, Historical Sociology, Military History, War Studies, International Relations, Geopolitics, and Russian and East European history. He is currently the Book Review Editor for Comparative Civilizations Review. Learn more about your ad choices. Visit megaphone.fm/adchoices

A memoir of a child's forced relocation to Siberia under Stalin's Gulag system reveals the potential for true human kindness in the face of extraordinary hardship.  In April of 1940, six-year-old Ida woke to the sound of pounding on her door. Soviet soldiers forcibly packed her and her mother onto a train with thousands of their neighbors and deported them to remote Siberia, leaving them stranded to survive the brutal winter in subhuman conditions. Looking back, Ida shares their struggles: foraging for food, trying to reunite with her imprisoned father, spending weeks in a desolate hospital with typhoid fever, and adapting to shifts in the political climate to make the long journey home to Poland. Ida published this acclaimed memoir in her native Polish in 2011. Here, Ida's granddaughter, Isabella Skrypczak, translates her babcia's words and provides additional context—including describing the remarkable life Ida has gone on to live as a pioneering doctor. In the vein of Anne Frank's The Diary of a Young Girl, A Polish Girl in Siberia: Surviving and Transcending Exile (Disruption Books, 2026) chronicles Ida's experiences on a lesser-known front of the Second World War. Together, Ida and Isabella reflect on how every small act of kindness contributed to Ida's liberation from exile and ability to build a life and a family. Her story celebrates the capacity of the human spirit to not only survive trauma but thrive beyond it.Ida Kinalska-Pietruska survived childhood exile to Siberia during the Soviet Union's World War II assault on Poland. When she returned to Poland as a teen, she began studying medicine. A pioneering endocrinologist, she founded the School of Endocrinology and Diabetology in Białystok and led the region's first endocrinology clinic for twenty years. Ida has authored more than four hundred publications, mentored countless other doctors, and collaborated across the international medical community, including using her research to make widely known the Chernobyl disaster's effects on people's endocrinological health. She has been honored with the Order Odrodzenia Polski, Poland's second-highest civilian state award, and two Doctor Honoris Causa titles, reflecting her resilience, brilliance, and global impact on science and humanity.Isabella Skrypczak is an author, intuitive healer, and former HR professional in Big Tech whose work bridges the seen and unseen. Born to Polish immigrants and raised in Houston, Texas, she spent every summer with her grandmother in Poland. When her grandmother's memoir gained national attention in Polish media, Iza felt called to translate it into English—an act of love, remembrance, and advocacy. As war returned to Eastern Europe, she recognized the urgency in sharing this history with the Western world. She lives in Austin, Texas, with her daughter, Kamila.Stephen Satkiewicz is an independent scholar with research areas spanning Civilizational Sciences, Social Complexity, Big History, Historical Sociology, Military History, War Studies, International Relations, Geopolitics, and Russian and East European history. He is currently the Book Review Editor for Comparative Civilizations Review. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week, BJ is joined by Dr. Robert Lustig. A Professor emeritus of Pediatrics, Division of Endocrinology at UCSF, and the author of numerous books you should read, including The Hacking of the American Mind, which is the subject of this week's interview. Dr. Lustig had a lot to say about the power corporations wield over us, Citizens United, and why you should cut as much sugar from your diet as you can. That's because, like the end result of Citizens United, sugar could kill you. Politically speaking of course.

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 4:05 Our hosts speak with Anna Kahkoska, MD, PhD, Joan Heckler Gillings Assistant Professor in the Department of Nutrition and adjunct assistant professor of medicine in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill, as well as Joshua Niznik, PharmD, PhD, assistant professor in the Division of Geriatric Medicine within the UNC School of Medicine. Their article, "Qualitative Analysis of Patient Portal Messages From Older Adults With Type 2 Diabetes," is available at doi.org/10.2337/doc25-0079. 14:10 Our hosts introduce Esben Thyssen Vestergaard, PhD, clinical associate professor in the Department of Clinical Medicine and Department of Pediatrics Aarhus University in Aarhus, Denmark. His article, "Clinic for Athletes With Type 1 Diabetes: Evaluation of a Structured Clinical Care Model for Physically Active Individuals," is available for free at doi.org/10.2337/doc25-0064. 21:40 Finally, Richard and Jane highlight some of their favorite articles from the May-June issue. Rezaeiahari, et al. Rural–Urban Differences in Use of Diabetes Self-Management Education and Support in Arkansas, 2015–2019 doi.org/10.2337/doc25-0065 Liu, et al. Trends in Nutrient Intake Among U.S. Adults by Diabetes Status: National Health and Nutrition Examination Survey 2011–2020 doi.org/10.2337/doc25-0076 Yanez Bello, et al. Barriers to the Adoption of Diabetes Technologies and the Implementation of Connected Insulin Pens in a Largely Minority Population With Type 1 Diabetes doi.org/10.2337/doc25-0072 Shehab, et al. Barriers to Effective Type 2 Diabetes Care in a Conflict-Affected Region of Syria: A Qualitative Study of Health Care Provider Perspectives doi.org/10.2337/doc26-0021 ElSayed, et al. Enhancing Physician Clinical Competency: A Cluster Randomized Trial of a Multimodal Online Educational Program in a Multinational Diabetes Workforce doi.org/10.2337/doci25-0007 Olesen, et al. A Danish Nationwide Cohort of Foot Health in Individuals With Diabetes From the Danish Foot Status Database doi.org/10.2337/doc26-0002 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Drs Kaniksha Desai and Sara Lubitz discuss secondary hypothyroidism. This podcast is intended for healthcare professionals only. Kaniksha Desai, MD, Associate Professor, Department of Internal Medicine, Endocrinology, Stanford University, Palo Alto, California Sara E. Lubitz, MD, Professor, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0

In this special edition of Diabetes Core Update, Neil Skolnik discusses PATHWEIGH, a novel obesity care process for primary care clinicians which has demonstrated a decrease in population weight gain. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Leigh Perreault, MD, Professor of Pedicine in the Division of Endocrinology, Metabolism and Diabetes, at the University of Colorado Denver School of Medicine, Aurora, CO Reference: Perreault, L., Pan, Q., Rodriguez, C. et al. Implementation and effectiveness of a care process to prioritize weight management in primary care: a stepped-wedge cluster-randomized trial. Nat Med 32, 645–652 (2026). 

In this episode, we discuss… ● How the brain controls reproductive hormones and communicates with the endocrine system.  ● How endocrine-disrupting chemicals (EDCs) interfere with brain-hormone communication. ● What EDCs are and how they disrupt normal hormonal signaling. The endocrine system explained through a simple "lock-and-key" hormone model. ● How EDCs can mimic or block natural hormones in the body. ● How EDCs disrupt hormone production, regulation, and overall balance in the body. ● The rise of synthetic chemicals after World War II and links to increasing endocrine and neurological disorders. ● The accidental discovery that BPA leaching from plastic caused reproductive harm in laboratory mice. ● Why endocrine disruption challenged the traditional idea that "the dose makes the poison." ● How chemicals like BPA can affect multiple hormone receptors at very low doses.....and so much more! Dr. Andrea Gore is Professor and Vacek Chair in Pharmacology at the University of Texas at Austin. Her research team is investigating fundamental mechanisms of how environmental endocrine-disrupting chemicals (EDCs) perturb the developing brain; sex differences in EDC actions; and transgenerational epigenetic effects. Dr. Gore's research has been funded continuously by the NIH, NSF, and foundations since 1992. She has published 4 books and over 200 scientific papers. She was Editor-in-Chief of Endocrinology from 2013-2017 and was lead author of the Endocrine Society's two Scientific Statements on EDCs, and the Endocrine Society-IPEN Guides to EDCs, most recently in 2024. Dr. Gore is very active in advocacy for, mentorship of, and education of trainees. Over 150 undergraduates, graduate students, and fellows have conducted independent research in her laboratory at the University of Texas at Austin. Dr. Gore feels fortunate to have multiple passions beyond her research in environmental health: playing violin in an orchestra and string quartet; running a turtle and tortoise sanctuary; and her rescue dogs. Andrea C. Gore, PhD Professor and Vacek Distinguished University Chair in Pharmacology The University of Texas at Austin andrea.gore@austin.utexas.edu http://sites.utexas.edu/gore/

Deirdre Tobias is an associate professor in the Department of Nutrition at the Harvard T.H. Chan School of Public Health and Brigham and Women's Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.K. Tobias and F.B. Hu. The 2025–2030 Dietary Guidelines for Americans — Progress, Pitfalls, and the Path Forward. N Engl J Med 2026;394:1969-1971.

A breakthrough in inflammatory support has arrived in the natural health market. PEA, which stands for palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad- spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injury.Multiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Dr. Mark Stengler, NMDLearn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

Senkt vegane Ernährung den Testosteronspiegel – oder ist das nur ein Fitness-Mythos? In dieser Folge sprechen wir über Testosteron, Soja, Cholesterin, Muskelaufbau, Krafttraining, Energiedefizite, Blutwerte und den wachsenden Trend rund um TRT. Wissenschaftlich eingeordnet, praxisnah erklärt und mit Blick darauf, was für vegane Sportlerinnen und Sportler wirklich relevant ist. ------------------------------------------------------------------------ Dominiks Buch zur pflanzenbasierten Sporternährung im UTB-Verlag: https://www.utb.de/doi/book/10.36198/9783838560328 Dominiks Gesundheitscommunity: www.gsundes-hannover.de Dominiks Online-Knie-Kurs: https://gsundes-hannover.de/knieschmerzen/ Dominiks Online-Rücken-Kurs: https://copecart.com/products/34bd5abb/checkout Marcs veganes Online-Fitness-Coaching: https://vegainer-academy.com/ Marcs Online-Kurs: https://www.copecart.com/products/a50f88f2/checkout ------------------------------------------------------------------------ Dieser Podcast wird unterstützt von der Firma Watson Nutrition. Die Firma bietet als einzige umfassend laborgeprüfte Nahrungsergänzungsmittel für eine optimierte Nährstoffversorgung. Zum Angebot zählen Multi-Supplemente, Mono-Supplemente, Sportsupplemente wie Kreatin oder auch Proteinriegel, Shakes und essenzielle Aminosäuren Mit dem Code veganperformance erhältst du 5 % Rabatt auf deine Bestellung.  Zur Firmenwebseite: Watson Nutrition ------------------------------------------------------------------------ Quellen: Wissenschaftliche Studien, Reviews und Leitlinien Allen, N. E., Appleby, P. N., Davey, G. K., & Key, T. J. (2000). Hormones and diet: Low insulin-like growth factor-I but normal bioavailable androgens in vegan men. British Journal of Cancer, 83(1), 95–97. Baillargeon, J., Kuo, Y. F., Westra, J. R., Urban, R. J., & Goodwin, J. S. (2018). Testosterone prescribing in the United States, 2002–2016. JAMA, 320(2), 200–202. Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996). The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. The New England Journal of Medicine, 335(1), 1–7. Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715–1744. Christou, M. A., Christou, P. A., Markozannes, G., Tsatsoulis, A., Mastorakos, G., & Tigas, S. (2017). Effects of anabolic androgenic steroids on the reproductive system of athletes and recreational users: A systematic review and meta-analysis. Sports Medicine, 47(9), 1869–1883. Cinar, V., Polat, Y., Baltaci, A. K., & Mogulkoc, R. (2011). Effects of magnesium supplementation on testosterone levels of athletes and sedentary subjects at rest and after exhaustion. Biological Trace Element Research, 140(1), 18–23. Corona, G., Rastrelli, G., Monami, M., Saad, F., Luconi, M., Lucchese, M., Facchiano, E., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2013). Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: A systematic review and meta-analysis. European Journal of Endocrinology, 168(6), 829–843. Demay, M. B., Pittas, A. G., Bikle, D. D., Diab, D. L., Kiely, M. E., Lazaretti-Castro, M., Lips, P., Mitchell, D. M., Murad, M. H., Powers, S., Rao, S. D., Scragg, R., Tayek, J. A., Valent, A. M., Walsh, J. M. E., & McCartney, C. R. (2024). Vitamin D for the prevention of disease: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 109(8), 1907–1947. Dubin, J. M., Jesse, E., Fantus, R. J., Bennett, N. E., Brannigan, R. E., Thirumavalavan, N., & Halpern, J. A. (2022). Guideline-discordant care among direct-to-consumer testosterone therapy platforms. JAMA Internal Medicine, 182(12), 1321–1323. European Association of Urology. (2026). Male hypogonadism. In EAU guidelines on sexual and reproductive health. Guisado-Cuadrado, I., Recacha-Ponce, P., Peinado, A. B., & Romero-Parra, N. (2026). Biochemical responses to experimentally induced short-term low energy availability in athletes: A systematic review. Scandinavian Journal of Medicine & Science in Sports, 36(3), Article e70249. Key, T. J. A., Roe, L., Thorogood, M., Moore, J. W., Clark, G. M. G., & Wang, D. Y. (1990). Testosterone, sex hormone-binding globulin, calculated free testosterone, and oestradiol in male vegans and omnivores. British Journal of Nutrition, 64(1), 111–119. Leproult, R., & Van Cauter, E. (2011). Effect of 1 week of sleep restriction on testosterone levels in young healthy men. JAMA, 305(21), 2173–2174. Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., Li, X., et al. (2023). Cardiovascular safety of testosterone-replacement therapy. The New England Journal of Medicine, 389(2), 107–117. Messina, M. (2010). Soybean isoflavone exposure does not have feminizing effects on men: A critical examination of the clinical evidence. Fertility and Sterility, 93(7), 2095–2104. Morden, N. E., Woloshin, S., Brooks, C. G., & Schwartz, L. M. (2019). Trends in testosterone prescribing for age-related hypogonadism in men with and without heart disease. JAMA Internal Medicine, 179(3), 446–448. Morton, R. W., Sato, K., Gallaugher, M. P. B., Oikawa, S. Y., McNicholas, P. D., Fujita, S., & Phillips, S. M. (2018). Muscle androgen receptor content but not systemic hormones is associated with resistance training-induced skeletal muscle hypertrophy in healthy, young men. Frontiers in Physiology, 9, Article 1373. Mountjoy, M., Ackerman, K. E., Bailey, D. M., Burke, L. M., Constantini, N., Hackney, A. C., Heikura, I. A., Melin, A., Pensgaard, A. M., Stellingwerff, T., Sundgot-Borgen, J. K., Torstveit, M. K., Jacobsen, A. U., Verhagen, E., Budgett, R., Engebretsen, L., & Erdener, U. (2023). 2023 International Olympic Committee's consensus statement on Relative Energy Deficiency in Sport. British Journal of Sports Medicine, 57(17), 1073–1097. Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., Platz, E. A., Ramanathan, L. V., & Lewis, R. W. (2018). Evaluation and management of testosterone deficiency: AUA guideline. The Journal of Urology, 200(2), 423–432. Prasad, A. S., Mantzoros, C. S., Beck, F. W. J., Hess, J. W., & Brewer, G. J. (1996). Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5), 344–348. Rao, P. K., Boulet, S. L., Mehta, A., Hotaling, J., Eisenberg, M. L., Honig, S. C., Warner, L., Kissin, D. M., Nangia, A. K., & Ross, L. S. (2017). Trends in testosterone replacement therapy use from 2003 to 2013 among reproductive-age men in the United States. The Journal of Urology, 197(4), 1121–1126. Reed, K. E., Camargo, J., Hamilton-Reeves, J., Kurzer, M., & Messina, M. (2021). Neither soy nor isoflavone intake affects male reproductive hormones: An expanded and updated meta-analysis of clinical studies. Reproductive Toxicology, 100, 60–67. Sagoe, D., Molde, H., Andreassen, C. S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis. Annals of Epidemiology, 24(5), 383–398. Travison, T. G., Araujo, A. B., O'Donnell, A. B., Kupelian, V., & McKinlay, J. B. (2007). A population-level decline in serum testosterone levels in American men. The Journal of Clinical Endocrinology & Metabolism, 92(1), 196–202. Travison, T. G., Vesper, H. W., Orwoll, E., Wu, F., Kaufman, J. M., Wang, Y., Lapauw, B., Fiers, T., Matsumoto, A. M., & Bhasin, S. (2017). Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe. The Journal of Clinical Endocrinology & Metabolism, 102(4), 1161–1173. Wankhede, S., Langade, D., Joshi, K., Sinha, S. R., & Bhattacharyya, S. (2015). Examining the effect of Withania somnifera supplementation on muscle strength and recovery: A randomized controlled trial. Journal of the International Society of Sports Nutrition, 12, Article 43. West, D. W. D., & Phillips, S. M. (2012). Associations of exercise-induced hormone profiles and gains in strength and hypertrophy in a large cohort after weight training. European Journal of Applied Physiology, 112(7), 2693–2702. Whittaker, J., & Wu, K. (2021). Low-fat diets and testosterone in men: Systematic review and meta-analysis of intervention studies. The Journal of Steroid Biochemistry and Molecular Biology, 210, Article 105878. Positionspapiere, Behörden und Informationsquellen Deutsche Gesellschaft für Ernährung. (2024). DGE veröffentlicht neues Positionspapier zu veganer Ernährung. Deutsche Gesellschaft für Ernährung. National Institutes of Health, Office of Dietary Supplements. (n.d.). Vitamin B12: Fact sheet for health professionals. Abgerufen am 21. Mai 2026. National Institutes of Health, Office of Dietary Supplements. (n.d.). Vitamin D: Fact sheet for health professionals. Abgerufen am 21. Mai 2026. U.S. Food and Drug Administration. (2025, 28. Februar). FDA issues class-wide labeling changes for testosterone products. U.S. Food and Drug Administration. World Anti-Doping Agency. (2026). The 2026 prohibited list. World Anti-Doping Agency. ‘They've invented a spurious pseudo-disease': Why are so many men being told they have low testosterone? (2026, 10. Mai). The Guardian.  

Today we're diving into a topic that so many people are curious about right now and that is concierge medicine. If you've ever felt rushed through a doctor's appointment, waited weeks to get in, or struggled to navigate the healthcare system, today's conversation is for you. MD² recently opened its Scottsdale practice in McCormick Ranch and is bringing a very different approach to healthcare. Their physicians care for only 50 families at a time, allowing for same day appointments for deeply personalized care and a true partnership in health and wellness. Joining us today is Dr. Bithika Thompson, a highly respected physician who spent more than a decade at Mayo Clinic Arizona and previously served as Chair of the Department of Endocrinology. She is nationally recognized for her work in diabetes, endocrinology, and patient centered care, and now she's helping bring MD²'s concierge model to Scottsdale alongside Dr. Leslie Thomas.  

Today we're diving into a topic that so many people are curious about right now and that is concierge medicine. If you've ever felt rushed through a doctor's appointment, waited weeks to get in, or struggled to navigate the healthcare system, today's conversation is for you. MD² recently opened its Scottsdale practice in McCormick Ranch and is bringing a very different approach to healthcare. Their physicians care for only 50 families at a time, allowing for same day appointments for deeply personalized care and a true partnership in health and wellness. Joining us today is Dr. Bithika Thompson, a highly respected physician who spent more than a decade at Mayo Clinic Arizona and previously served as Chair of the Department of Endocrinology. She is nationally recognized for her work in diabetes, endocrinology, and patient centered care, and now she's helping bring MD²'s concierge model to Scottsdale alongside Dr. Leslie Thomas.  

Gugs Mhlungu is joined by Dr. Ankia Coetzee, Endocrinologist and Faculty member at Tygerberg Hospital and Stellenbosch University, unpacking the renaming of PCOS to PCOS and why experts believe the shift could lead to more accurate diagnoses, better treatment approaches, and improved support for patients living with the condition. Gugs Mhlungu gets you ready for the weekend each Saturday and Sunday morning on 702. She is your weekend wake-up companion, with all you need to know for your weekend. The topics Gugs covers range from lifestyle, family, health, and fitness to books, motoring, cooking, culture, and what is happening on the weekend in 702land. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

What is cultural distress? It is a negative response rooted in a cultural conflict where the patient lacks control over their situation. It results in more physiologic effects on the body resulting in allostatic overload. To prevent this, healthcare practitioners must use strategies such as cultural humility to help patients navigate healthcare. Come find the best ways to deliver culturally sensitive care in any setting.

Cortisol after cancer is the conversation nobody on my care team had with me. I was diagnosed with breast cancer in 2021 — invasive ductal carcinoma, stage one, grade two. I went through lumpectomy, radiation, ovarian suppression, and two years on an aromatase inhibitor before I had to come off because my bones were already in osteoporosis. Throughout all of it, my nervous system was screaming. My cortisol was running hot all day long, confirmed by a Dutch test. And not one doctor told me what stress was doing to my body or how to mitigate it. In this solo episode of Not Today Cancer, I'm walking you through the seven activities that lowered my cortisol...broken into the things that don't cost a dime (meditation, breathwork, walking outside, unplugging) and the things that do (acupuncture, energy healing, therapy). I'm also sharing the actual research behind each one, so you know this isn't woo...it's documented science.  What you'll learn: • Why cortisol is wrecked after a cancer diagnosis (and why mine was high long before) • The symptoms of high cortisol most breast cancer survivors miss • How mindfulness meditation protected the cortisol rhythm of breast cancer survivors in a randomized controlled trial • Why a single session of slow breathing drops cortisol immediately • The "nature pill" research showing 20–30 minutes outside lowers cortisol 21% per hour • Why the NCCN officially recommends acupuncture for cancer survivors If you're a breast cancer survivor, caregiver, or anyone whose body has been running on fumes...this episode is for you. We don't get the option of not mitigating stress. Pick one thing on this list and start tomorrow. Disclaimer: This episode reflects my personal experience and a summary of public research. It is not medical advice. Always consult your care team.

In this episode, I'm breaking down the four pillars of recomposition to help you shrink your body fat, build lean muscle, and reclaim the energy you had in your 20s. For 30 years, the fitness world has preached the same rule: you have to "bulk" to gain muscle, or "cut" to lose fat. But modern science shows us a different path. It is entirely possible to do both at the same time through a process called Body Recomposition. Sponsors: Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Caraway Home: carawayhome.com/drjoshaxe (Use code DRJOSHAXE) for an exclusive discount Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: ⁠⁠⁠https://www.youtube.com/@drjoshaxe?sub_confirmation=1⁠⁠⁠ 

This week's 640-360 looks at the weight loss drugs like Ozempic & Wegovy and Greg Brady spoke to Dr. Daniel Drucker, endocrinologist based at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital and Professor of Medicine in the Division of Endocrinology at University of Toronto. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailToday we're going somewhere I've been wanting to go for a while — into the neuroscience of oxytocin. Not oxytocin as the cuddle hormone, though it is that too. Oxytocin as a brain-changing, nervous system-healing, plasticity-promoting substance that you can actually learn to stimulate intentionally through your daily practices.What we cover:What oxytocin actually is — beyond the "love hormone" label, it is a neuroplasticity agent that promotes new neuron growth, reshapes synaptic connections, and helps the brain become more open to change and healingThe oxytocin-safety loop — how oxytocin and the parasympathetic nervous system reinforce each other, and why this is the biological basis for healing happening in relationship and community rather than in isolationThe research on meditation — particularly loving-kindness, gratitude, and compassion-based practices — and why the heart-opening, relational quality of the practice matters more than meditation style aloneNadi Shodhana (alternate nostril breathing) — the honest framing of what the research does and doesn't yet show, and why the vagus nerve pathway makes it one of the most direct routes to oxytocin release we haveSeven everyday oxytocin releasers — gentle touch and self-massage, warmth, face-to-face community, humming and chanting, gratitude — and how each maps onto Ayurvedic practices you may already be doingFree downloads: Grab the one-page guide — 7 Ways to Release Oxytocin Today — with the science and Ayurvedic wisdom behind each practice. Click HereAnd my Self Abhyanga Guide HereResearch ReferencesOxytocin & Neural PlasticityPekarek, B.T., Hunt, P.J., & Arenkiel, B.R. (2020). Oxytocin and Sensory Network Plasticity. Frontiers in Neuroscience, 14, 30. https://doi.org/10.3389/fnins.2020.00030Froemke, R.C., & Young, L.J. (2021). Oxytocin, Neural Plasticity, and Social Behavior. Annual Review of Neuroscience, 44, 359–381. https://doi.org/10.1146/annurev-neuro-102320-102847Meditation & OxytocinBellosta-Batalla, M., et al. (2020). Increased salivary oxytocin and reduced anxiety in a mindfulness and compassion-based intervention. Mindfulness. (Referenced in Frontiers in Endocrinology, 2024)Machida, S., Sunagawa, M., & Takahashi, T. (2018). Oxytocin release during the meditation of altruism and appreciation (Arigato-Zen). International Journal of Neurology Research, 4, 364–370.Resources:Free Masterclass:  The Alchemy of the Perimenopause PortalAyurvedic Dosha Quick Reference GuideAbhyanga Self Massage GuideWeekend Nervous System ResetNourished For Resilience Workbook Find me at www.nourishednervoussystem.comand @nourishednervoussytem on Instagram

Learning Objectives:By completion of this program, attendees will be able to:InpatientIdentify the latest diabetes wearable devices and their approach to inpatient use.Determine the approach to perioperative management of diabetes medications.Recognize and manage endocrinopathies from use of immune checkpoint inhibitors.OutpatientIdentify candidates for Type 1 Diabetes antibody screening and the significance of early detection for disease-modifying therapies.Formulate a comorbidity screening strategy for patients with Type 2 Diabetes, focusing on Metabolic Associated Steatotic Liver Disease (MASLD) evaluation.Appropriately screen patients with hypertension for primary hyperaldosteronism, accurately interpret lab results, and identify common medication interferences that may impact diagnostic testing.Speakers:Jennifer Bernard, MD, Medical Director Endocrinology, St. Anthony Hospital, Medical Director of Specialty Services, Common Spirit Denver MetroRani Kulkarni, MD, Medical Director, Comprehensive Diabetes Care Program, Saint Joseph Medical Center (Tacoma, WA), Virginia Mason Franciscan HealthModerator:Thomas Frederickson, MD, FACP, SFHM, MBA, System VP Hospital Medicine Operations

Fasting is one of the most powerful healing practices in human history—it's free, requires zero equipment, and your body is literally designed for it. But while it sounds simple, there is a wrong way to do it, especially when it comes to the hormonal "engine switch" that happens in the first 24 hours. In this episode, I walk you through exactly what happens in your body during a 3-day fast, from clearing out "zombie cells" to the 60% drop in aging markers. Sponsors: Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Caraway Home: carawayhome.com/drjoshaxe (Use code DRJOSHAXE) for an exclusive discount Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: ⁠⁠https://www.youtube.com/@drjoshaxe?sub_confirmation=1⁠⁠ 

According to the International Diabetes Federation (IDF) 2024 data, India has 89.8 million adults living with diabetes. More than any other country in the world. Yet most people still do not understand what diabetes actually is, how it develops, or what they can do to prevent or manage it.This week on Run with Fitpage, Vikas sits down with one of India's foremost authorities on the subject.Dr. Anoop Misra is the Chairman of Fortis C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology in New Delhi, and a former Honorary Physician to the Prime Minister of India. A Padma Shri awardee and recipient of the Dr. B.C. Roy Award — India's highest medical honour — he has spent over 45 years studying what diabetes does to the Indian body and why Indians are uniquely vulnerable to it at lower body weights than the rest of the world.In this episode, the conversation starts from the very beginning — what blood sugar actually is, how insulin works, and why the body moves from healthy to pre-diabetic to diabetic over years without sending obvious signals. Dr. Misra explains why Indians develop diabetes at a BMI of 23 to 25 when Western guidelines only flag risk at 30, and why being slim does not mean being safe.Read more from his research here: Google ScholarDr. Anoop Misra's Books:Diabetes with Delight (English): AmazonDiabetes Ke Saath Bhi Khushaal Jeevan (Hindi): AmazonIn this episode we covered :→ What blood sugar actually is and why the body needs it→ How insulin works — and what goes wrong when it stops working→ The difference between Type 1 and Type 2 diabetes, and why insulin is not the enemy→ Why weight is the thick tree and blood sugar is just one of its branches→ The real cost of ignoring diabetes — from vision loss to kidney failure→ Why grip strength is as important as blood pressure and should be treated as a vital sign→ How to start managing diabetes or pre-diabetes from today — diet, exercise, and disciplineAbout Vikas Singh:Vikas Singh, an MBA from Chicago Booth, worked at Goldman Sachs, Morgan Stanley, APGlobale, and Reliance before coming up with the idea of democratizing fitness knowledge and helping beginners get on a fitness journey. Vikas is an avid long-distance runner, building fitpage to help people learn, train, and move better.For more information on Vikas, or to leave any feedback and requests, you can reach out to him via the channels below:Instagram: @vikas_singhhLinkedIn: Vikas SinghTwitter: @vikashsingh101Subscribe To Our Newsletter For Weekly Nuggets of Knowledge!

Amanda Banks is a consultant and a physician at the Corporal Michael J. Crescenz VA Medical Center. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. A. Banks. GLP-1 Receptor Agonists and Eating Disorders — Cause for Concern. N Engl J Med 2026;394:1665-1667.

How does metabolic health govern your long-term vitality, energy, and quality of life? Dr. Priya Jaisinghani outlines why monitoring some basic lifestyle actions could prevent so many common chronic diseases.In this episode of TRUST ME I KNOW WHAT I'M DOING, we sit down with NYU endocrinologist and obesity medicine specialist Dr. Priya Jaisinghani to decode the complexities of metabolic health.Forget the quick fixes and diet culture — Dr. Jaisinghani walks us through a science-backed approach to understanding metabolic function as a comprehensive system. We move beyond the scale to explore how muscle mass, cardiovascular health, and hormonal balance dictate your long-term vitality.In this episode, we cover:• Why "metabolic health" is the true metric for longevity and quality of life.• Actionable steps to improve insulin sensitivity and sustain energy levels.• How to navigate health misinformation and advocate for yourself in the medical system.The critical link between your daily habits—like sleep and hydration—and your organ function.Subscribe for weekly conversations that serve as a mirror and window into the global Indian and South Asian experience.--------------------------Chapters:00:00 Introductions04:07 Defining Metabolic Health07:29 Personalizing the Approach13:03 Bridging Knowledge Gaps in Health16:43 Healthy Choices for Young Adults19:29 Redefining Fun and Social Activities20:40 Empowering Patients as Advocates22:39 Sponsor Break - Travelopod24:06 Tailoring Health Approaches for South Asians28:15 Dismantling Weight Bias and Stigma31:08 Building a Weight Neutral Approach35:01 Understanding GLP-1 Medications37:30 The Role of Nutrition in Metabolic Health39:09 The Importance of Sleep in Metabolic Health40:51 Building Trust in Patient RelationshipsConnect with Dr. Jaisinghanihttps://nyulangone.org/doctors/1942738547/priya-jaisinghaniBig shout outs to Anagha on her 50th, and to my friend, pediatrician colleague, and adolescent medicine guru Dr. Lauren Hartman,  whose latest book Freeing Children and Young Adults from Shame, Scales, and Stigma is available now. Support the Show: If you enjoyed this episode, please subscribe and leave a review on Spotify, Apple, or Amazon or wherever you podcast!TRUST ME I KNOW WHAT I'M DOING is proudly brought to you by TRAVELOPOD, with personalized travel support to help you explore the wonders of the world.  Start your next journey at vacation.travelopod.com

We have a great show planned today and will talk about why there has been a significant rise in people of all ages using Creatine. To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health.A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Is creatine only useful for resistance / power type activities?There are a variety of athletic events, not just resistance/power activities, which may benefit from creatine supplementation.-Creatine supplementation with carbohydrate or carbohydrate and protein has been reported to promote greater muscle glycogen storage than carbohydrate supplementation alone.-May reduce muscle damage and/or enhance recovery from intense exercise.-Individuals supplementing their diet with creatine experienced less muscle damage, inflammation, and muscle soreness in response to running 30-km as well as during 4-weeks of intensified training.-There is evidence that athletes who supplement with creatine during training experience fewer musculoskeletal injuries, accelerated recovery time from injury and less muscle atrophy after immobilization.-Creatine supplementation (with or without glycerol) has been reported to help athletes hyper-hydrate and thereby enhance tolerance to exercise in the heat-There is evidence from animal models that creatine supplementation is neuroprotective and can reduce the severity of spinal cord injury, cerebral ischemia, and concussion/traumatic brain injury. This evidence was so compelling that the International Society of Sports Nutrition recommended that athletes engaged in sports that have a potential for concussion and/or spinal cord injury take creatine for its neuroprotective effects.Learn more about Dr. StenglerLearn more about Emerald Labs Creatine Health

Sara Gerke is an associate professor of law and at the European Union Center at the University of Illinois Urbana-Champaign. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. S. Gerke, R.B. Parikh, and I.G. Cohen. Utah's Prescription-Renewal Pilot Program — Autonomous AI Managing Patient Care. N Engl J Med 2026;394:1561-1563.

The lads sit down with Prof Neil Gittoes to discuss SCOOP (Screening in the Community to Reduce Osteoporotic Fractures). The study was a large UK trial (12,483 women, aged 70–85) finding that screening for fracture risk using FRAX and targeting treatment to high-risk individuals significantly reduces hip fractures. Professor Gittoes is a Consultant Endocrinologist at the Queen Elizabeth Hospital Birmingham (QEHB), and Honorary Professor of Endocrinology at the University of Birmingham where he is Head of the Centre of Endocrinology, Diabetes and Metabolism (CEDAM). More importantly he is Chair of the board of trustees at the Royal Osteoporosis Society

Can liver disease be prevented? Could lifestyle play a major role in reducing the risk and in the treatment if liver disease? What are the major causes of liver diseases? Dr. Ajaz is a highly trained clinician with a deep passion for Lifestyle Medicine. She holds certifications from the British Society of Lifestyle Medicine and the International Board of Lifestyle Medicine. I has the pleasure of speaking to her in her home in London where we talked about all things liver health, disease prevention and treatments.  In this deep dive, we cover:  The prevalence of liver disease What are the major factors that cause liver disease The signs and symptoms of the condition The role of lifestyle medicine in prevention, treatment and management  Dr. Ajaz earned her MPhil in Biochemistry and Molecular Biology, followed by a PhD in Diabetes, Endocrinology, and Metabolism from King's College London in 2016. With over 17 years of experience as both a medical doctor and a researcher in the translational field, she has dedicated her career to investigating non-invasive biomarkers and preventative strategies for early detection of chronic metabolic diseases. https://www.kch.nhs.uk/about/get-involved/groups-and-events/livfit/ https://www.provigilant.co.uk/wellness https://hssh.health/consultants/dr-saima-ajaz/

A breakthrough in inflammatory support has arrived in the natural health market. PEA, which stands for palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad- spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injury.Multiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Dr. Mark Stengler, NMDLearn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.

What if one of the biggest health threats on Earth… is something you can't see, taste, or even fully measure yet? In this urgent solo episode, Darin breaks down the rapidly escalating crisis of microplastics and nanoplastics infiltrating our bodies, water systems, and environment. What was once dismissed is now being acknowledged at the highest levels, with government agencies scrambling to understand and contain the damage. From plastics crossing the blood-brain barrier to disrupting hormones and carrying toxic chemicals deep into human tissue, this episode exposes the hidden cost of modern convenience, and more importantly, gives you practical, immediate actions you can take to protect yourself and your family. What You'll Learn Why microplastics are now considered a global health emergency How plastics accumulate in your body and environment The shocking truth about nanoplastics crossing the blood-brain barrier How plastics act as endocrine disruptors affecting hormones The connection between plastics and inflammation, fertility, and disease Why tap water and bottled water are both major exposure sources The role of PFAS ("forever chemicals") in long-term health damage How to filter and detox microplastics from your body Emerging science on breaking down plastics using bacteria and plants Simple, actionable steps to dramatically reduce your exposure Chapters 00:00:00 – Welcome to SuperLife 00:02:12 – Opening: committing to a clean, conscious life 00:02:27 – Fatal conveniences and why awareness matters 00:02:46 – Government officially flags microplastics as a crisis 00:03:04 – $100M+ initiatives to understand plastic contamination 00:03:38 – Microplastics in drinking water and daily exposure 00:04:20 – Plastics found in babies and human brains 00:04:45 – Why we still don't understand the full damage 00:05:08 – Nanoplastics crossing the blood-brain barrier 00:05:33 – Plastics as endocrine disruptors 00:06:02 – Hormonal imbalance, inflammation, and toxicity 00:06:30 – PFAS and the "forever chemical" crisis 00:06:59 – The #1 rule: stop using single-use plastic bottles 00:07:27 – Hidden dangers of "BPA-free" plastics 00:07:58 – Why you can no longer trust tap water 00:08:30 – The importance of high-quality water filtration 00:09:11 – Reverse osmosis systems and best practices 00:10:17 – Detox strategies: sweating and sauna use 00:10:59 – Fiber and plant-based diets binding toxins 00:11:24 – Medicinal mushrooms and beta glucans 00:11:52 – Microbes that break down plastic polymers 00:12:32 – Plant-based flocculants (okra, fenugreek) removing plastics 00:13:20 – Bio-sponges and advanced filtration innovations 00:13:46 – Magnetic separation technology 00:14:27 – Microplastics from clothing and laundry systems 00:15:16 – AI-assisted filtration and regulatory changes 00:15:55 – Light-activated breakdown of plastics 00:16:03 – Boiling water to remove up to 90% of microplastics 00:16:33 – Practical emergency water filtration methods 00:16:59 – Creating a low-toxicity lifestyle at home 00:17:20 – Final message: take control and protect your health 00:17:32 – Outro     Thank You to Our Sponsors Tru Niagen – Boost NAD+ levels for cellular health and longevity. Get 20% off with code DARIN20 at truniagen.com. Shakeology – Shakeology-All in One Nutrition: Get 15% off with code SUPERLIFE at Shakeology.com.     Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien     Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness     Key Takeaway: "We are living in a world where convenience has quietly introduced toxins into nearly every aspect of our lives, but you are not powerless. The moment you become aware, you can take action. And the small choices you make every day: what you drink from, how you filter your water, what you put into your body, can dramatically shift your long-term health and your family's future."     Bibliography/Sources: The News Hook — EPA CCL6 & STOMP Initiative Chemical & Engineering News. (2026, April 3). US government targets microplastics for research and potential drinking-water regulation. American Chemical Society. https://cen.acs.org Environmental Protection Agency. (2026, April 2). EPA takes bold action to ensure drinking water is safe from microplastics, pharmaceuticals, and potential hidden contaminants [Press release]. https://www.epa.gov/newsreleases Environmental Protection Agency & Department of Health and Human Services. (2026, April 2). EPA, HHS announce historic actions to protect Americans from microplastics and safeguard drinking water [Press release]. https://www.epa.gov/newsreleases Inside Climate News. (2026, April 3). EPA flags microplastics as 'priority' water contaminants, but the move doesn't guarantee regulation. https://insideclimatenews.org National Public Radio. (2026, April 2). EPA flags microplastics, pharmaceuticals as contaminants in drinking water. https://www.npr.org STAT News. (2026, April 2). EPA to put microplastics on study list of contaminants in drinking water. https://www.statnews.com The New Lede. (2026, April 2). EPA flags microplastics as 'priority' contaminants in drinking water. https://thenewlede.org U.S. Government. (2026). Public comment docket: EPA-HQ-OW-2022-0946. https://www.regulations.gov The Science — Brain Invasion & Cellular Damage ACS Environment & Health. (2025). Neurotoxicity of micro- and nanoplastics: A comprehensive review of CNS impacts. American Chemical Society. https://pubs.acs.org Journal of Nanobiotechnology. (2025). Maternal nanoplastic exposure led to impaired neuronal development in the fetal cortex. Springer Nature. PubMed Central. (2023). Micro-/nanoplastics breach the blood-brain barrier: Biomolecular corona's role revealed. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov PubMed Central. (2024). A review on micro- and nanoplastics in humans: Translocation of barriers and potential health effects. National Institutes of Health. https://pubmed.ncbi.nlm.nih.gov PubMed Central. (2025). Overall effects of microplastics on brain. National Institutes of Health. https://pmc.ncbi.nlm.nih.gov ScienceDirect. (2025). Mechanisms of micro- and nanoplastics on blood-brain barrier crossing and neurotoxicity. Elsevier. https://www.sciencedirect.com The Science — Endocrine Disruption & Gut Health eClinicalMedicine. (2026). Phthalates attributed to nearly 2 million preterm births globally. The Lancet. Frontiers in Cellular and Infection Microbiology. (2024). Microplastics, human health, and the gut microbiome. Frontiers. https://www.frontiersin.org Frontiers in Endocrinology. (2023). A review of the endocrine disrupting effects of micro and nano plastic in mammals. Frontiers. International Journal of Molecular Sciences. (2025). Micro- and nanoplastics as disruptors of the endocrine system. MDPI. https://www.mdpi.com PubMed Central. (2025). Microplastics, endocrine disruptors, and oxidative stress. National Institutes of Health. Solutions — Filtration & Global Removal Technologies ACS Applied and Environmental Microbiology. (2024). Eco-microbiology: Discovering biochemical enhancers of PET biodegradation by Piscinibacter sakaiensis. American Chemical Society. ACS Omega. (2025). Thermostability and activity improvements of PETase from Ideonella sakaiensis. American Chemical Society. Environmental Science & Technology Letters. (2024). Drinking boiled tap water reduces human intake of nanoplastics and microplastics. American Chemical Society. https://doi.org/10.1021/acs.estlett.4c00081 Srinivasan, R., et al. (2025). Fenugreek and okra polymers as treatment agents for the removal of microplastics from water sources. ACS Omega. https://doi.org/10.1021/acsomega.4c07476 Yoshida, S., et al. (2016). A bacterium that degrades and assimilates poly(ethylene terephthalate). Science.  

Drs Kaniksha Desai and Maria Papaleontiou discuss thyroid biology throughout the lifespan, with a focus on older adults This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0 Kaniksha Desai, MD, Associate Professor, Department of Internal Medicine, Endocrinology, Stanford University, Palo Alto, California Maria Papaleontiou, MD, Assistant Professor, Research Assistant Professor, Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan; Research Associate Professor, Institute of Gerontology, University of Michigan, Ann Arbor, Michigan

Guest: Dr. Kotaro Sasaki is an Associate Professor at the University of Pennsylvania. In this episode, he discusses how his lab uses human pluripotent stem cells to model germ cell development and endocrine organs such as the testis and adrenal gland. He highlights progress toward in vitro gametogenesis, including generating spermatogonial-like cells and reconstructing testicular environments, as well as recent advances in building adrenal organoids with zonal architecture. He also explores the scientific, translational, and ethical challenges of creating functional human gametes, and emphasizes the importance of developmental biology in guiding stem cell-based approaches. Featured Products and Resources: Get a free wallchart on the derivation and applications of hPSCs. Take your human pluripotent stem cell cultures further with mTeSR™ Plus from STEMCELL Technologies. The Stem Cell Science Round Up Stage-Specific Cell Competition – Cell competition in gastruloids is stage-specific and driven by relative p53 levels during pluripotency exit. Modeling Pediatric Brain Tumors – Scientists have enabled robust generation and drug testing of patient-derived pediatric brain tumor organoids. Immune Reprogramming in Heart Failure – Engineered dendritic cells reduce cardiac fibrosis and improve heart function by modulating immune responses. Overcoming Hypoxia in Islets – Inhibiting zinc transport enhances stem cell–derived islet survival and function by improving angiogenesis and hypoxia resistance. Photo Reference: Courtesy of Dr. Kotaro Sasaki. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Intermittent fasting may help with blood sugar, appetite, fat loss, and energy. But many people do it wrong.  In this episode, Professor James Betts, one of the world's leading experts on meal timing and its metabolic effects, explains what fasting actually is, how long you need to fast to see changes, and the key mistakes that can stop the benefits. Today, we break down what happens in your body when you stop eating and explain why it may support weight loss and blood sugar control, but also why fasting doesn't work for everyone. You will learn why breakfast may not matter, why the 5:2 diet often fails, and why eating even small amounts can stop a true fast. By the end of this episode, you will understand what counts as a real fast, how long your eating window may need to be, why longer is not always better if you cannot stick to it, and why planning your first meal matters, because hunger can drive poor choices. If fasting can work, but is not magic, what actually makes the difference: the timing, the consistency, or simply eating less?

Host: Darryl S. Chutka, M.D.  Guest: Vinaya Simha, M.B.B.S., M.D.  For years, we saw very little change in the management of type 2 diabetes. However, over the past decade, numerous new pharmacologic treatment options, innovations in glucose monitoring, and new insulin delivery systems have become available. We've also seen a new philosophy regarding the goals of diabetes management. What are the latest medications for diabetes and is there still a role for the older, traditional options? How have the improvements in technology affected the management of diabetes and what are the newly established goals for managing patients with the disease? These are some of the questions I'll be asking my guest, Dr. Vinaya Simhah from the Division of Endocrinology, Diabetes and Metabolism at the Mayo Clinic as we discuss “Diabetes and Novel Therapies for Diabetes”.  This episode of Mayo Clinic Talks is the third of three podcasts celebrating a remarkable milestone in Mayo Clinic's history – the 100th anniversary in April this year of our renowned journal, Mayo Clinic Proceedings. Proceedings first appeared in April 1926 and has been in continuous publication ever since. Many significant clinical breakthroughs, pioneered at Mayo Clinic, were first published in the journal, and today the journal brings primary care providers relevant, timely, and important papers on conditions and disorders that are frequently seen in the practice. A great deal of content in Mayo Clinic Proceedings is freely available for you to browse—just go to https://www.mayoclinicproceedings.org to incorporate this terrific resource in your library. Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

In this special edition on Continuous Ketone Monitoring our host, Dr. Neil Skolnik will discuss this new technology – its promise and its application. This special episode is supported by an independent educational grant from Abbott. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Guillermo Umpierrez, M.D.,  Professor of Medicine, Division of Endocrinology, Clinical Director of the Diabetes and Metabolism Center at Emory University School of Medicine, Director of the Diabetes and Endocrinology Section and Clinical Research Unit at Grady Memorial Hospital, Atlanta, Georgia. Member of the ADA Professional Practice Recommendation Committee, and Chair of the ADA Consensus Report on Hyperglycemic Crises in Adults with Diabetes.   Reference: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care 2024;47:1257–1275 | https://doi.org/10.2337/dci24-0032

Modern medicine has come a long way in its fight against diabetes. We now have continuous glucose monitors (CGM) and automated insulin delivery (AIDs) systems. These have revolutionized patient care. The FDA has approved devices for use in pregnancy as “nonadjunctive use” (meaning they may be used alone), although capillary finger stick assessments are currently still considered the Gold Standard. While the most robust data in support of CGMs is for preexisting Type 1 DM (Class B or beyond) and Type 2, there is recent growing support for CGM use in GDM patients, although some limitations still apply. Listen in for details.1. Feig DS, et al; CONCEPTT Collaborative Group. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25;390(10110):2347-2359. doi: 10.1016/S0140-6736(17)32400-5. Epub 2017 Sep 15. Erratum in: Lancet. 2017 Nov 25;390(10110):2346. 2. Benhalima K, Durnwald C, Sweeting A et al.Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statementThe Lancet Diabetes & Endocrinology, 2025; 14, 157-1773. Salmen BM, Reurean-Pintilei D, Salmen T, Bohîlțea RE. Exploring Continuous Glucose Monitoring in Gestational Diabetes: A Systematic Review. Life (Basel). 2025 Aug 28;15(9):1369. doi: 10.3390/life15091369. PMID: 41010309; PMCID: PMC12470761.4. Wyckoff JA, Lapolla A, Asias-Dinh BD, et al.Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. 20255. American Diabetes Association Professional Practice Committee for Diabetes*; 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S321–S338. https://doi.org/10.2337/dc26-S0156. Burk J, Ross GP, Hernandez TL, Colagiuri S, Sweeting A. Evidence for improved glucose metrics and perinatal outcomes with continuous glucose monitoring compared to self-monitoring in diabetes during pregnancy. Am J Obstet Gynecol. 2025 Sep;233(3):162-175. doi: 10.1016/j.ajog.2025.04.010. Epub 2025 Apr 10. PMID: 40216177.7. Linder T, et al; GRACE study collaborative group. Glycaemic control and pregnancy outcomes with real-time continuous glucose monitoring in gestational diabetes (GRACE): an open-label, multicentre, multinational, randomised controlled trial. Lancet Diabetes Endocrinol. 2026 Jan;14(1):50-61. doi: 10.1016/S2213-8587(25)00288-8. Epub 2025 Nov 24. PMID: 41308662.8. Valent AM, et al. Real-Time Continuous Glucose Monitoring in Pregnancies With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Diabetes Care. 2025 Sep 1;48(9):1581-1588. doi: 10.2337/dc25-0115. PMID: 40730104; PMCID: PMC12368369.9. Kusinski LC, et al. Continuous Glucose Monitoring Metrics and Pregnancy Outcomes in Women With Gestational Diabetes Mellitus: A Secondary Analysis of the DiGest Trial. Diabetes Care. 2025 Aug 19:dc250452. doi: 10.2337/dc25-0452. Epub ahead of print. PMID: 40828742; PMCID: PMC7618813.10. García-Moreno RM, et al. Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. Diabet Med. 2022 Jan;39(1):e14703. doi: 10.1111/dme.14703. Epub 2021 Oct 13. PMID: 34564868.11. Amylidi-Mohr Set,.et al (DipGluMo): an open-label, single-centre, randomised, controlled trial. Lancet Diabetes Endocrinol. 2025 Jul;13(7):591-599. doi: 10.1016/S2213-8587(25)00063-4. Epub 2025 May 26. Erratum in: Lancet Diabetes Endocrinol. 2026 Mar;14(3):e6. doi: 10.1016/S2213-8587(25)00403-6. PMID: 40441173.

In this episode of Better Edge, Northwestern Medicine Endocrinologist Ioannis Papagiannis, MD, reviews key updates from the 2025 American Thyroid Association Differentiated Thyroid Cancer Guidelines. He highlights refined, pathology specific risk stratification and a growing emphasis on individualized care. The discussion explores treatment de-escalation strategies, including active surveillance, surgical decision making, selective radioactive iodine use and tailored follow up, all designed to improve outcomes while minimizing overtreatment.

Deb (00:03.606)Within the next seven months, up to 1.5 million Americans could lose access to a medication that they’ve relied on for decades. Not because it’s dangerous, but because a pharmaceutical giant may have lobbied the FDA to eliminate their competition. And if you’re one of them, your doctor may already have told you about this issue and stopped prescribing it.This isn’t a conspiracy theory. This is documented in federal court filings. This is happening right now. And the company that stands to profit, well, they’re the same ones manufacturing the only product that might survive.Today on Let’s Talk Wellness Now, we’re exposing the desiccated thyroid extract crisis, the corporate manipulation behind it, and what you need to do right now to protect your health. Stay with me because I’m about to share what could save your access to the medication keeping you alive.Welcome back to Let’s Talk Wellness Now, the show where we uncover the root causes of chronic illness, expose regulatory capture in healthcare, and empower you with the tools to advocate for yourself. I’m Dr. Deb, naturopathic doctor, your medical detective, and today we’re diving into one of the most consequential and corrupt healthcare decisions affecting patients right now. If you or someone you love takes Armour thyroid, NP thyroid, or any desiccated thyroid extract,for hypothyroidism or if you’ve struggled to find a thyroid medication that actually works for your body, this episode is absolutely critical. And if you have celiac disease, gluten sensitivity or corn allergies, what I’m about to reveal will make your blood boil. Now grab your cup of coffee, don’t forget your notebook and settle in because what’s happening to this medication right now is a masterclass in how pharmaceutical companies use regular Deb (02:06.544)agencies to eliminate competition, control markets, and price gouge patients. And I have all the receipts. Deb (02:20.982)Let me start with what might surprise you. Desiccated thyroid extract, or DTE as we call it, is actually one of the most oldest thyroid medications in the world. And I mean old. From the 1890s through 1970, this was the standard treatment for hypothyroidism.Now let’s really dive into that. From the 1890s to the 1970s, this was standard hypothyroidism treatment.In 1965 alone, and this is documented in peer-reviewed literature published in the Journal of Clinical Endocrinology and Metabolism, approximately four out of every five prescriptions for thyroid hormone in the United States were of natural desiccated thyroid preparations.The Journal of Clinical Endocrinology and Metabolism is a very high-end journal. Now think about that. This wasn’t some fringe therapy. This was mainstream medicine. Armour Thyroid, the most recognizable brand name, has been manufactured since the early 1900s, well over a century ago.and this is cited again in NIH bookshelf. When the FDA was officially established in 1938, Arbor thyroid was already on the market. And this is important and I want you to understand why. Under the federal Food, Drug and Cosmetic Act, any drug that was already being marketed before 1938 was automatically grandfathered into the system. That means it didn’t have to Deb (04:08.112)go through the formal FDA approval process. And this again is cited under the Federal Food, Drug and Cosmetic Act, grandfathered drugs and exemptions. And this is crucial to understanding what happens next. By the 1970s, synthetic levothyroxine, brand name Synthroid and generics became the preferred treatment. Hmm, wonder why?It was easier to standardize, came into consistent doses, and worked well for most patients, and could be mass manufactured. By the 1980s, levothyroxine had largely replaced desiccated thyroid in clinical practice, according to the American Thyroid Association 2014 guidelines for the treatment of hypothyroidism. But here’s what matters. Some patients…a very significant minority of them, never felt right on levothyroxine alone. Despite their lab work looking normal, they still had fatigue, brain fog, weight gain, cold intolerance, and depression.These patients often found relief when they switched back to their desiccated thyroid, which contains both T4 and T3 hormones, the way human thyroid naturally produces them. And this is not anecdotal. This is documented in randomized double-blind crossover studies published in Endocrine Practice.For decades, that was fine. Their doctors prescribed it, insurance sometimes covered it, patients were getting better, and the system worked really well. Until August 6th of 2025, just a short time ago, everything changed. On that date, the FDA sent letters to manufacturers, importers, and distributors of desiccated thyroid extract products stating that these medications would need an approval. Deb (06:04.654)a biologics licensed application, a BLA, to remain legally on the market. And this is cited in the FDA’s official statement, FDA’s actions to address unapproved thyroid medications. understand it says unapproved thyroid medications. However, desiccated thyroid, specifically Armour, has been approved since 1938. And this was dated August 6th through 7th, 2025.This wasn’t a guideline. This wasn’t a suggestion. It was an endorsement of action. And the timeline they gave them? Well, just 12 months to transition patients to another medication before enforcement action could begin.This was also cited by an FDA notice to the industry, animal derived thyroid products notice to industry, August 6th, 2025. Now do the math, that means August 2026, seven months from now, 1.5 million Americans currently taking this medication. And this number comes from the FDA official statement, citing that it’s an estimation of 1.5 million patients receiving prescriptions for these medications.could potentially lose their thyroid access. Now, here’s where it gets interesting. The FDA didn’t wake up in August of 2025 and decide to regulate desiccated thyroid after a century. This decision has a much longer backstory. And understanding that backstory is critical to understanding what’s really happening in this industry.The shift started in 2022. Back in September of 2022, over three years ago, an FDA branch chief sent a letter to the National Associations of Boards of Pharmacy noting that the agency had decided to designate DTE as a biological product, which would affect its eligibility for compounding. Deb (08:13.972)This also is cited in an FDA letter to the National Association of Boards of Pharmacy September 2022.Then two months later, in November of 2022, the FDA’s Office of Compounding Quality and Compliance sent a softer letter acknowledging that many Americans take medication to treat hypothyroidism and some choose to take DTE products. The letter stated that the FDA would focus enforcement on cases that pose the greatest public health risks, such as serious adverse offense or serious product quality or adulteration.also is cited by an FDA letter from Francis G. Bromel, the director, Office of Compounding Quality and Compliance, November of 2022. Now, let me just think about this for a second. If this drug has been on the market since the 1800s, been FDA approved since 1938, would we not have seen a health crisis long before 2022?I honestly don’t know of any other drug that’s been around this long that’s used by this many people. Now granted, I haven’t done the research on it either, which I can do for you guys, but I’m just thinking if a drug is on the market today and it causes harm, it doesn’t make it three years, five years before you see lawsuits everywhere. Why are there no lawsuits on this drug? Why are there no major reactions that people are seen having?Hmm, just thought. But here’s the pattern. The FDA was already laying the groundwork back in 2022, testing the waters, signaling where this was headed. The August 2025 action. Then this came down. Deb (10:09.806)August 6, 2025, the FDA announced its position publicly and sent formal letters to all DTE manufacturers, importers, and distributors. This was cited by the FDA Enforcement Action August 6, 2025, letters to manufacturers, importers, distributions of DTE products. The agency stated several concerns. First, DTE products have experienced quality and dosing issues.The FDA cited, and I’m quoting directly from their statement, over 500 adverse events reported associated with DTE products from 1968 to 2025. From 1968 to 2025, we had 500 adverse reactions? What is that math equate to?A couple a year? Come on guys, this is insane! With a substantial increase, you, between 2019 and 2020 that the agency suggested was related to voluntary recalls of sub-potent or super-potent products.This was cited in the FDA statement, over 500 adverse events reported associated with ADT products from 1968 through 2025.Second, the agency expressed concern about batch inconsistency. According to the FDA’s official statements, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Okay, this was cited in the FDA statement, tablets made from the same manufacturing batches may not always provide the same thyroid hormone levels. Thirdly, and I want to actually let’s back up. I want you to remember I said that Deb (12:11.216)because further down in this podcast, we’re going to talk about this. This is an important point to remember. Thirdly, the agency raised concerns about potential impurities from animal source material, including potential for viral contamination due to the animal source and supraphysiological levels of T3.the FDA statement on impurities, viral contamination and super physiological T3 levels. Now I will tell you, I’ve been prescribing armarithograde for 20 years. I’ve rarely seen a super physiological dose given of T3 in lab results, unless the patient takes their medication like four or five hours before you do the blood test, then you’ll see a false rise because you’re actually seeing the medication. You’re not seeing people walking aroundsuperphysiological T3 levels. Nobody would like that feeling. So anyway, I digress. Now let me pause here because this is where I need to give you some context that the FDA hasn’t quite emphasized yet. Of course, we have another connection and it is the China connection.So the FDA’s concerns about contaminated drugs and quality issues don’t exist in a vacuum. In 2024, the U.S. over 828,000 metric tons of pharmaceuticals, seven times the level from 2000. And here’s the kicker. China and India supply the majority of active pharmaceutical ingredients. APIs for U.S. generics accounting for 70 to 80 % of the total genericdrug supply. According to Reuters industry report in 2024, they state that China supplies 82 % of the APIs for critical drugs. Deb (14:08.204)Got to question that, right? Why are we giving all of our drug formulas to China and allowing them to import them into our country? In fact, roughly 20 % of the critical drugs have APIs exclusively sourced from China. And China controls 80 to 90 % of the global production for antibiotics and other key compounds. This was also cited by Reuters industry data thatcontrols 80 to 90 percent of the global production for antibiotics and other key compounds. Now just think about this. They control 80 to 90 percent of our medication. They control 20 percent of our critical drugs and we just put what kind of tariff on them? Hmm.In 2025 alone, the FDA issued multiple warning letters to foreign manufacturers for contamination issues and failure to follow good manufacturing practices. This is also cited by the FDA warning letters 2024 through 2025 and multiple citations to foreign manufacturing facilities. This is a systematic problem affecting the entire US drug supply, not just desiccated thyroid.So when the FDA suddenly became concerned about DTE quality and contamination, part of that concern was legitimate. But this is crucial. The same inconsistencies and contamination issues exist across the entire generic drug supply. And the FDA has not taken the same enforcement action against them. Let that sink in.They have not taken the same enforcement action against the other drug companies. So what’s behind all of this? Where is this all coming from? Hmm. Let’s address something directly, because you deserve to know it. And I’m going to cite my sources precisely so that when the medical boards have something to say about this, and they might, I have a documentation for every single word that I am about to speak. Deb (16:24.878)According to the court documents filed in October 2025, in the case ofa urine, a urine. I’m going to say that wrong. Pharmaceuticals versus Dr. George Tidmarsh from ABBV, the multinational pharmaceutical company that manufactures armor thyroid, reportedly petitioned the FDA in 2024, asking the agency to reclassify DTE as a biologic and to prohibit other manufacturers from selling unlicensed DTE products unless they havehad an investigational new drug application, we call this an IND, and a clinical development program aimed at eventual approval. This is cited in the court filing a Urena pharmaceuticals lawsuit versus Dr. George Tidmarsh, October 2025, reported by Fierce Pharma. Now let me explain why this matters and why this is one of the most brazen examples of regulatory capture I’ve ever seen in my career.AbbeVee is one of the world’s largest pharmaceutical companies. In 2024, they reported over $54 billion in revenue. Drop the mic on that one.They have the resources, the regulatory expertise, the legal teams, and the financial capacity to navigate a biologics license application process that costs between $500 million and $1 billion. Let that sink in. Deb (18:07.882)A drug that’s been on the market since the 1800s that was grandfathered in 1938 that’s making plenty of money right now. They’re going to spend 500 million to $1 billion to get a biologics license application. Why would they do that? Well, we’re about to find out. Most otherDTE manufacturers, smaller companies like Acela Pharmaceuticals, which makes NP-thyroid, and RLC Labs, which made WP-thyroid, do not have those same resources. And this is cited in Pharma Voice in 2025. Why a treatment older than the FDA is getting new regulatory scrutiny. So when you petition the FDA to reclassify a drug in a way that requires this type of expensivetime-consuming biological approval, you’re not just asking for safety. You’re asking to eliminate your competitors from the marketplace. Now, I want to be very precise here. These allegations are documented in federal court filings, and it hasn’t been approved in court. It’s also been reported by multiple industry sources, including Fierce Pharma. But I’m telling you,what has been reported in legal proceedings, not stating it as an absolute fact because you deserve to know the difference and because I have to protect my license. Now, what do we know for certain?AbbeVee is working on a biologics license application for Armour thyroid through clinical trials called Avantia. This is cited by the AbbeVee corporate statement 2025 Avantia clinical trial for Armour thyroid. A cell of pharmaceuticals has been pursuing BLA approval for NP thyroid for seven years since 2017 and it completed its phase two trials successfully in 2025. They’re now moving Deb (20:15.448)into Phase 3 trials. This is also cited by the Acela Pharmaceuticals CEO statement 2025 seven-year pursuit for BLA approval completed Phase 2 trials moving to Phase 3.RLC Labs, which manufactured WP thyroid, has made no public announcement about pursuing BLA approval and really probably don’t have a plan to do this since they’ve been off the market for some time now. About five years, I think maybe a little longer. Here’s the market manipulation.If only ABBV is successful and obtains a BLA approval for Armour thyroid, that company would effectively have a monopoly on the DDT market. And in pharmaceutical markets, monopolies historically lead to price increases.We’ve seen this pattern over and over again when turning pharmaceuticals acquired Daraprim and raised their price from $13.50 to $750 per tablet overnight. When Myelin raised EpiPen increased prices by 400 % when insulin manufacturers colluded to raise prices in lockstep. This is the playbook.use regulatory barriers to eliminate your competition and then exploit pricing power. For a drug that’s been on the market since the 1800s, guess corporate greed is everywhere. They’re not making enough money on this product already and they’re taking advantage of the rules that they can manipulate their competition by. And here’s what really makes me furious. The American Thyroid Association, the professional organization Deb (22:06.672)representing endocrinologists sent letters to the FDA commissioner on October 8th of 2025 and September 18th of 2025.advocating for continued patient access to DTEs. This is cited in the American Thyroid Association statement and letter to the FDA commissioner dated October 8th, 2025 and September 18th, 2025. The American Association of Clinical Endocrinologists issued a statement on September 9th of 2025 supporting equitable access and personalized medicine for DTE. This was also cited in the American AssociationAssociation of Clinical Endocrinologists, AACE, statement dated September 9th, 2025. Even the medical establishment, which has historically favored levothyroxine, is saying, wait, this is going too far. Patients need access to this medication. But the FDA is moving forward anyway. Why? Well, where does it always lead us? Follow the money trail.Okay, so I need to explain what a biologics license application actually is because this is where the rubber meets the road for what’s going to happen to pricing and availability. What is a BLA?A BLA is a biologics license application. It’s a formal request submitted to the FDA to market a biologic product in the United States. A biologic is defined under the Public Health Service Act section 351 as a product derived from or made using living material, in this case, animal thyroid glands. And this is cited in the FDA definition for biologic products. So they’re putting armor thyroid right Deb (23:57.377)right up with stem cells and exosomes. Think about that. Stem cells and exosomes cost thousands of dollars per application because of how they have to be harvested, stored, freezed, all of that. But we’re talking about a thyroid gland. Good Lord, people.Unlike regular drug applications for synthetic medications which follow a simpler pathway, the BLA process is designed for complex biological products like monoclonal antibodies, vaccines, and gene therapy products. It’s a much more expensive, much more time-consuming process. The BLA processis what manufacturers have to do. And we’re going to talk about that. So according to Reprocell and Forge Biologics analysis of the FDA’s BLA process, here’s what companies need to submit. First, they need to complete a clinical trial data, phase one, two, and three trials, proving safety and efficacy for desiccated thyroid. Haven’t we done that since it’s been on the market since the 1800s? Just saying.This means they have to conduct large randomized controlled trials comparing it to levothyroxine, measuring safety outcomes, efficacy outcomes, and quality of life metrics. Second,Chemistry, Manufacturing and Controls, CMC’s data. Detailed information about how the product is manufactured, quality control measures, stability testing and specifications that must be met for every batch. Third, preclinical and animal safety data. Fourth, labeling and product information. Now, I think we have labeling and product information. Deb (25:53.717)since the 1800s? But just saying. Fifth, they need Pharma Covigilance Plan, a detailed plan for monitoring safety after the product is on the market. Haven’t they had to do that since the 1800s? And they have to have a timeline. And this is the critical part. The FDA’s standard review time for a BLA is 10 months.That’s after the application is deemed complete and accepted for filing. So this is cited by the FDA standard review timeline, BLA submission, and FDA review.Now, before you even get to filing, you need to conduct the clinical trials and compile all the data that’s typically several years of work. How are you going to prove safety and effectiveness in a large clinical trial long term? What do they consider? What do they deem long term? Three months, six months, a year, two years. These companies had 10 months.Well, maybe 12. They did it a year in advance. But unless you knew this was coming, how are you going to put together a trial, enroll the people, have all the trial components set up and ready to go in less than 12 months unless you knew it was coming beforehand? Even ifhad started all their clinical trials in 2024, completing them, compiling the data, and getting a complete application ready for submission, this would likely take you through mid-2026, then add another 10 months for FDA review. We’re looking at 2027 at the earliest for most of these companies to receive a BLA application. Deb (27:54.319)But the FDA gave the manufacturers until August of 2026. That’s approximately 19 months from when the August 2025 letters were sent. Most companies cannot reasonably complete the BLA approval in that timeframe. And when I’m talking about the 19 months, I’m talking about the information they would have had earlier. Now the cost.This gets me even more frustrated. Why are we spending this kind of money? The BLL process is extraordinarily expensive. The current FDA user fee for a BLA submission is approximately $483,560 just for the filing fee. And this is cited at the FDA user fees prescription drug user fee rates for 2025.The full cost of conducting clinical trials, CMC studies, and all the supporting documentation typically ranges from $500 million to over $1 billion, depending on the scope of the trials and the complexity. And this is cited in JAMA’s network, Open2023. A cell of pharmaceuticals has been pursuing the BLA approval since 2017. That’s eight years. And it’s just now.moving into phase three trials with a planned enrollment of approximately 300 patients. This is cited by the Acela Pharmacies CEO statement of 2025. Now that’s unusual. That’s typical for this process. This is not unusual. This is typical for this process to take seven, 10 years to get approval for this. So if Abby’s the one that requested this,Abby V. And Acela started this in 2017. Was Abby V threatened by Acela that Acela might get this approval and it would be quietly done without anybody seeing it? And maybe Abby V would be left out of the market after a century? Who knows? It’s possible. Deb (30:13.112)But for smaller manufacturers without billions in revenue, this cost is completely prohibitive. And this is why this matters. When you push an old established medication through an extraordinary, expensive approval process with a compromised timeline, one of three things happen. First, only the largest companies can afford it, creating a monopoly. And when that happens, the company that holds the only approved product can set pricing withminimal competitive pressures. Two, smaller manufacturers can’t afford it and their products disappear and the market shrinks and access decreases. Three, we see a combination of both and who pays the price? Literally, patients do. Now here’s whereThere’s something I want you to really think about because this is where the regulatory argument falls apart when you look at it carefully. The FDA’s concern about DTE is that, and I’m quoting their official statement, tablets from the same manufacturing batches may not always provide the same thyroid hormone levels. This is from their FDA statement.And that’s a legitimate quality concern, right? It is. Thyroid medications have a narrow therapeutic window like any other hormone, meaning the difference between an effective dose and the dose that causes problems can be quite small. But here’s what the FDA doesn’t emphasize. Generic drugs have the exact same dosing inconsistency issue, and it’s considered acceptable and has been since we allowed generics on the market.So how does a generic drug dose work anyway? Well, for generic drugs to be approved as bioequivalent to a brand name medication, the FDA requires that the generic drugs bioavailability fall within 80 to 125 % of the brand name product. Isn’t that a dose inconsistency? Deb (32:22.894)from the brand name medication? 800 or sorry, 80 to 125%. According to the pharmacy times analysis of the FDA’s bioequivalent standards, the 80 to 125 % bioequivalence rule means that a generic drug can have 20 to 45 % variability compared to the original brand product.Now, most generics are much closer than that. The FDA study data shows that the mean difference for an AUC value between generic and reference products is about three and a half percent in the two year post-Waxman hatch period, and 80 % of the generics fall within a five percent range. But the FDA’s regulations allow for that much higher variability. And this is cited in an FDA study data mean difference for AUC.Now, let me put this in plain language. A patient could take a generic levothyroxine tablet where one batch provides, say, 75 micrograms of an active thyroid hormone. And the next batch from a different manufacturer, a different generic manufacturer, could provide up to 93.75 micrograms, 125 % of that 75. That’s an 18 microgram difference.in the same prescribed dose. Now, this is considered acceptable and patients tolerate it and this system works.Yet the FDA’s argument against DTE is that batch-to-batch inconsistency is unacceptable and requires this expensive biologic approval? That’s a double standard. So why is batch inconsistency acceptable for generic levothyroxine, but supposedly unacceptable for desiccated thyroid? I’ll give you the regulatory answer. Deb (34:29.366)because DDT is a biological product derived from an animal tissue and the FDA considers biological products to require more rigorous control. That’s the regulatory answer, but I’ll give you the real answer.because there’s no billion dollar pharmaceutical company with a patent pending on generic levothyroxine who petitioned the FDA to regulate their competitors more strictly. The inconsistency argument is legitimate, but it’s selectively applied. And that matters when you’re trying to understand whether this is really about patient safety or whether it’s about market control.Now I want to talk about something that hasn’t gotten nearly enough attention in this discussion and it’s something that makes me absolutely furious. What is Armour Thyroid? According to the official prescribing information published by AbbeV and available through rxabbev.com and the FDA’s daily med database, Armour Thyroid contains the following inactive ingredients. Calcium steroid,dextrose derived from corn, mycocrystalline cellulose,sodium starch glycolate and a opadri white coating. Now let’s talk about dextrose. Dextrose is a sugar derived from corn and while manufacturers claim that the corn derived dextrose in armor thyroid is gluten free, here’s the problem. Cross contamination during corn processing can introduce gluten proteins especially if the corn is processed in facilities that also handle Deb (36:18.808)wheat, barley, or rye. Corn sensitivity is extremely common in patients with celiac disease and non-celiac gluten sensitivity, and studies show that up to 50 % of the celiac patients react to corn proteins due to molecular mimicry, and the corn proteins look similar enough to gluten that the immune system attacks them. And this is cited by RestartMD.com.And here’s what’s documented in peer-reviewed medical literature in a 2023 case report published in Case Reports in Endocrinology. These researchers documented five patients with gluten intolerance or celiac who were taking natural desiccated thyroid. Three of those patients also reported lactose intolerance. Now these patients had to switch from DTE to liquid levothyroxine formulations to avoid the inactiveSo here’s my question. If AbbeV becomes the only manufacturer with an approved DTE product and their formulations contain corn-derived dextrose that triggers reactions in celiac patients, what are those patients supposed to do? They can’t take armor because of the corn. They can’t take compounded DTE because the FDA is banning compounding of these biologics. They can’t take NPKsor WP thyroid because those companies may not survive the BLA process. So they’re left with a synthetic version of levothyroxine which may not work for them.Now the NP thyroid and WP thyroid difference. Now here’s what’s interesting according to drugs.com comparison of inactive ingredients and P thyroid and P thyroid has calcium steroid dextrose also derived from corn, mineral oil, multi-crystalline cellulose. Deb (38:19.31)cross carmelicin sodium and a opadri to white. So NP thyroid also has corn-derived dextrose. WP thyroid on the other hand was specifically formulated to be hypoallergenic according to ROC labs, but it’s no longer available and its ingredients were inulin from chicory root and medium chain triglycerides. No corn, no gluten, no common allergies. So todayWe do not have a glandular thyroid, a DTE, that is not potentially contaminated with gluten. Yet, patients with autoimmune thyroid disease are supposed to avoid gluten.Now, some of these people can handle a DTE and many cannot, so that argument could be a mute point. But at the end of the day, the one product that we had that was designated for patients with multiple chemical sensitivities, celiac disease and coron allergies, has been off the market for a long time already.We have a monopoly problem. So if ABBV becomes the only approved manufacturer, patients with these celiac diseases and corn allergies will either be forced to take a medicine that makes them sick and triggers their immune reaction or switch to a synthetic that doesn’t adequately treat their hypothyroidism or choose to go without treatment. This is not hypothetical. This is real patients with real medical needs who are about to lose accessto the only formulation that works for their body. And the FDA’s response is silence. Deb (40:07.69)Now I want to highlight something that hasn’t gotten nearly enough attention in this discussion. Compounding pharmacies. What is a compounding pharmacy? Compounded medications are custom made by licensed pharmacists to meet a patient’s specific needs. Maybe you need a different strength that was commercially available, but you have an allergy to a filler or a dye in the commercial product. Maybe you need a liquid formulation or instead of a tablet or you need a capsule. That’s when compoundingin. And the FDA’s, this is the FDA’s definition of compounding. And for decades, compounding pharmacies have been making desiccated thyroid extract for patients who needed customization. Some patients couldn’t take the commercial products because of the dyes and the fillers, and some needed strengths that were not available. And these compounding pharmacies filled the gap.But reclassification changes everything. When the FDA reclassified DTE as a biologic in 2022 and reinforced that decision in August of 2025, explicitly stated, and I’m quoting directly from the FDA’s official statement, these unapproved animal-derived thyroid medications are not eligible for compounding because these products are regulated as biologic products under the Public Health Service Act.How can that be? These products have been approved since 1938 and the Biologics Act didn’t go into effect or doesn’t go into effect until August of 2026.So how in 2022 were they able to say that the compounding pharmacies could not make these products? Anyway, what this means is after August 2026, compounding pharmacies will no longer be permitted to compound a desiccated thyroid extract, even for patients with specific medical needs. Now, compounding pharmacies can still compound T4 and T3 separately, synthetic versions of levothyroxine and liothyronine, according to Deb (42:12.728)healing dose compounding pharmacy. These pharmacists can create custom ratios of these two synthetic hormones to approximate what a patient was receiving from a DTE. But that’s not the same thing. Some patients respond better to the whole DTE preparation than to a compounded synthetic combination. And for patients with specific allergies to standard fillers like your celiac patients that I just talked about, losing the ability to get a compounded DTE alternative isreal hardship. This is going to be a ripple effect. For a subset of patients, maybe 5 to 10 percent of those on DTE compounding was their lifeline and it was their way to get a medication formulation that worked for their unique body. When compounding goes away, these patients lose that option as well and for some it will be a significant problem. Now let’s talk about what this likely means for your wallet.The current pricing right now, according to SingleCare and GoodRx, Armour Thyroid costs approximately $150 to $157 for a 90-day supply of 60-milligram tablets, about $1.67 per tablet. With discount cards, some patients can get it down to $101 to $152 for a 90-day supply.Generic levon thyroxine costs about $70 for a 90 day supply, less than half that price. And p-thyroid costs approximately $133 for a 90 day supply of 60 milligrams with a discount card about $83 to $101.What happens after we get BLA approval? Well, here’s the pharmaceuticals pricing model. When a company spends 500 million to $1 billion to bring a product to market, including conducting massive clinical trials, the cost tens of millions of dollars they recoup in that investment through pricing power. And this is cited in the pharmaceutical pricing models. If ABBIEV is the only company with an approved BLA of DTE, Deb (44:18.248)They have pricing power. They don’t have competitors. They can set their price, whatever they want. And historically, when drugs transition from grandfather status, which is basically unregulated to formal formally approved status, prices often increase significantly, not always, but often. And typically they have to get re-approval for insurance. SoTouring Pharmaceuticals acquired DARPM and raised the price again from $1,350 to $750 overnight, a 5,000 % increase. This is the playbook.Let’s talk about insurance coverage. This is the other consideration. Insurance companies sometimes have different coverage policies for approved versions versus unapproved drugs. And right now, many insurance plans cover armor thyroid or NP thyroid, even though they’re technically unapproved because they’ve been on the market for decades and patients are on them. Once a drug becomes formally approved, insurance companies may have new contractual relationships, prior authorization requirements, or preferred drugs.list that could affect your coverage. If 1.5 million people have to get a prior auth for their insurance to cover this new medication, this is going to drive the doctor’s offices crazy. We do not have the staff to man this. We do not have the manpower. We do not have the time. This is going to interrupt people’s ability to get their medications. This is going to create chaos within the system. And some patients might see better coverage, but manymost likely are going to see worse coverage and some might find themselves in a situation where they need to try to get the drug approved first or get an approval for something else like levothyroxine and they’re going to have to document that it didn’t work and the documentation that they had from 20 years ago is probably not going to be enough because it’s not documented anywhere. It’s lost in the system after 10 years. So for patients the practical takeaway is expect Deb (46:25.774)a price increase. I would say possible, but I don’t think that’s true. think you’re going to see a price increase if they get approved. Expect possible insurance complexities, budget accordingly, talk to your insurance company now about what your coverage is going to look like in 2027 if they even know. And if you want my honest assessment of what is likely to happen,I’ll give you a scenario, 30 % likelihood. The FDA enforces the August 26 deadline and DTE products not approved by then are pulled from the market. Patients will have 30 to 90 days to transition to other medications. Some patients suffer significant symptom relapse. Compounding for DTE becomes illegal and this disruptiveness of the system creates a real hardship. Scenario two.which is 50 % likely. This is actually what the FDA commissioner, Marty McCreary suggested on August 13th of 2025 when he posted on social media. The FDA is committed to pursuing the first ever approval of desiccated thyroid access pending results of the ongoing clinical trials. In the meantime, we’ll ensure access for all Americans. Hopefully that continues. What this likely means is the FDA uses enforcement discretion to allow continuedsales while approvals are being pursued and the deadline gets extended. Maybe patients get access for another two to three years while companies work on a BLA approval. This would be the least disruptive scenario, but it’s also legally uncertain because the enforcement letters have been formally rescinded. And scenario three, which is 20 % likelihood, one or two companies get BLA approval. Those products stay on the market at higher product prices and companies, products, other companiescompanies, products are pulled, the market shrinks, availability is limited, prices are higher, but patients can still get something. This is likely if a seller successfully completes phase three trials for NP-thyroid. And my assessment is based on the regulatory language and the enforcement letters that have not been rescinded yet, that the pattern of FDA enforcement, I believe scenario two enforcement discretion with an extended time frame is most likely what we’re going to see. Deb (48:49.488)doesn’t mean patients should sit back and do nothing. It means you should be prepared for change while advocating for access. If you want to keep Arm or Thigh Right on the market, 1.5 million people need to start talking about this publicly and flooding our Congress people, Bobby Kennedy, the FDA, with what you want to see happen. We have the ability to shape this and to change this with our voice. But if we sit back on our laurels and we do absolutelynothing. What is going to happen is what the FDA wants to have happen and ABV wants to have happen because they’re going to simply think people don’t give a shit. And if the American people are going to be lazy and not want to step forward and actually start using their voice for some good and instead of just going to social media and bitching and hoping something is going to happen, well, then we’re going to get what we deserve. But if you start taking someaction and you start advocating for the things that you want. Contacting your representatives, contacting your U.S. tell them the FDA has done this. Many of them may not know this, may not be on their radar. Tell them what you want. Start going after this. Start writing to the FDA Commissioner’s Office. They have a website. They have a Commissioner’s Office at fda.hhs.gov. Be responsible.respectful, but be firm. Explain your scenario. How long you’ve been on DTE. Why levothyroxine doesn’t work. What symptoms you experience when not adequately treated. How this decision will affect your quality of life and your pocketbook. Let’s do something proactive. So let’s consider this. Moving forward, work with your provider who understands the regulatory landscape around DTE. You can discuss the evidence for and against combination therapy.You can monitor for thyroid function with free T3 and free T4 testing, not just TSH. If you’re willing to try individualized approaches, you can do that. If you need help finding a functional medicine provider who understands this issue, come to serenityhealthcarecenter.com or explorethevanari.com. It’s a self-directed functional medicine support group. And right now what is happening is going to shape how history Deb (51:19.024)is made with not just armor thyroid, but many drugs to come. And it is important for you to take action. So I want to thank you for joining me today on Let’s Talk Wellness Now. This episode is about far more than thyroid medication. It’s about your right to personalized medical treatment. It’s about your regulatory capture and corporate influence. And it’s about what happens when billion dollar companies shape healthcare policy in ways that reduce patient choice and increase their profits.this episode resonates with you or you know somebody who’s going to be affected by desiccated thyroid, please share it. Post it on social media, send it to your doctor, email it to your representatives, tag AbbeVee, tag FDA. Make noise because the only way we stop this is if we make it too politically costly for them to continue. Your voice truly matters. Your health truly matters and you deserve access to treatments that work best for your unique body.If you’re ready to explore comprehensive personalized health care that puts you in control, visit us at SerenityHealthCareCenter.com. Learn more about functional medicine approaches to thyroid and beyond and explore my new platform, Venari.com, which is a self-directed functional medicine tool. Thank you for joining me today. Until next time, I’m Dr. Deb reminding you, your health is your responsibility, your choice, and your right. Be well, stay informed, fight back.and I’ll see you in the next episode. And if you’re looking for a full citation list of this episode, you can head over to letstalkwellnessnow.com and I will post all the citations for you so you have them in your arsenal as well. Thank you again.The post Episode 259 – The Desiccated Thyroid Crisis: FDA's Unseen Impact & Corporate Manipulation first appeared on Let's Talk Wellness Now.

Learn how to increase testosterone naturally with five proven strategies that actually work. This episode covers liver detoxification, fasting, brown fat activation, omega-3 fish oil, and targeted supplements like vitamin D, carnitine, and ashwagandha. Discover the connection between fatty liver, metabolic syndrome, and low testosterone—and why supporting your body naturally may be the key before considering TRT injections. (478 characters) FEATURED PRODUCT Zen – Adrenal Support by MSW Nutrition One of the most overlooked influences on testosterone is chronic stress. When cortisol stays elevated, testosterone production declines. Zen is designed to support nervous system balance and stress resilience with bovine adrenal gland extract, helping manage the cortisol-testosterone connection discussed throughout this episode. If you're working on increasing testosterone naturally, supporting your stress response is a foundational step—and Zen was built for exactly that.

Providing primary health care in a war zone presents some extraordinary challenges. This presentation delves into the complex world of healthcare delivery amid conflict and chaos.

Drs Kaniksha Desai and Jacqueline Jonklaas discuss the mechanisms, clinical presentations, and management strategies for medication-associated thyroid effects. This podcast is intended for healthcare professionals only. Kaniksha Desai, MD, Associate Professor, Department of Internal Medicine, Endocrinology, Stanford University, Palo Alto, California Jacqueline Jonklaas, MD, PhD, Professor, Division of Endocrinology, Georgetown University, Washington, DC To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0

We have a great show planned today and will talk about why there has been a significant rise in people of all ages using Creatine. To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health.A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Is creatine only useful for resistance / power type activities?There are a variety of athletic events, not just resistance/power activities, which may benefit from creatine supplementation.-Creatine supplementation with carbohydrate or carbohydrate and protein has been reported to promote greater muscle glycogen storage than carbohydrate supplementation alone.-May reduce muscle damage and/or enhance recovery from intense exercise.-Individuals supplementing their diet with creatine experienced less muscle damage, inflammation, and muscle soreness in response to running 30-km as well as during 4-weeks of intensified training.-There is evidence that athletes who supplement with creatine during training experience fewer musculoskeletal injuries, accelerated recovery time from injury and less muscle atrophy after immobilization.-Creatine supplementation (with or without glycerol) has been reported to help athletes hyper-hydrate and thereby enhance tolerance to exercise in the heat-There is evidence from animal models that creatine supplementation is neuroprotective and can reduce the severity of spinal cord injury, cerebral ischemia, and concussion/traumatic brain injury. This evidence was so compelling that the International Society of Sports Nutrition recommended that athletes engaged in sports that have a potential for concussion and/or spinal cord injury take creatine for its neuroprotective effects.Learn more about Dr. StenglerLearn more about Emerald Labs Creatine Health

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-476 Overview: Melatonin is widely used and often perceived as a safe, natural solution for insomnia. However, a new preliminary study raises concerns about long-term melatonin use and increased risk of heart failure, hospitalization, and all-cause mortality in patients with chronic insomnia. In this episode, we review the findings, discuss how they fit with existing evidence, explore limitations, and offer practical guidance for clinicians counseling patients about sleep supplements. Episode resource links: American Heart Association Scientific Sessions 2025 – Abstract 4371606 AHA Scientific Statement: Multidimensional Sleep Health and Cardiometabolic Risk (Circulation, 2025) Li et al. Lancet Diabetes & Endocrinology, 2024 American Academy of Sleep Medicine Clinical Practice Guidelines AHA Life's Essential 8 & Sleep Health Resources Guest: Mariyan Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-476 Overview: Melatonin is widely used and often perceived as a safe, natural solution for insomnia. However, a new preliminary study raises concerns about long-term melatonin use and increased risk of heart failure, hospitalization, and all-cause mortality in patients with chronic insomnia. In this episode, we review the findings, discuss how they fit with existing evidence, explore limitations, and offer practical guidance for clinicians counseling patients about sleep supplements. Episode resource links: American Heart Association Scientific Sessions 2025 – Abstract 4371606 AHA Scientific Statement: Multidimensional Sleep Health and Cardiometabolic Risk (Circulation, 2025) Li et al. Lancet Diabetes & Endocrinology, 2024 American Academy of Sleep Medicine Clinical Practice Guidelines AHA Life's Essential 8 & Sleep Health Resources Guest: Mariyan Montaque, DNP, FNP-BC   Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.

Dr. Mary Rosser, obstetrician gynecologist and director of Fazzalari Women's Health at NewYork-Presbyterian The One and Columbia, joins us to explain how the endocrine system functions and how external chemicals can disrupt hormonal signals that influence metabolism, fertility, cancer risk, and long-term health. She details the most common sources of endocrine disruptors — including plastics, personal care items, cleaning products, and pesticides — and shares clear, manageable strategies for reducing everyday exposure. Dr. Rosser's guidance empowers listeners to make small, sustainable changes that can help protect hormonal well‑being.   Chapters: 00:00:00 — Understanding Hormones and Endocrine Disruptors 00:05:01 — Health Effects Linked to Endocrine Disruptors 00:09:55 — Everyday Sources and How to Reduce Exposure 00:17:28 — Can the Body Recover? Practical Steps and Final Takeaways   Key Topics Covered What hormones are and how the endocrine system works What endocrine disruptors are and how they interfere with hormone signaling How endocrine disruptors enter the body (skin, food, air) Health impacts: metabolism, fertility, cancer risk, and chronic conditions Common sources of disruptors (plastics, BPA, phthalates, cosmetics, cleaning products, pesticides, microplastics) Practical ways to reduce exposure in daily life How to monitor hormone health and when to talk to a doctor The body's ability to recover once exposure is reduced   Takeaway Message This episode empowers listeners to understand how everyday chemicals can interfere with the body's delicate hormonal system — and shows that small, practical changes in the products we use and the foods we choose can meaningfully reduce exposure.   Expert Guest Dr. Mary L. Rosser, M.D., Ph.D., NCMP is an obstetrician gynecologist and the director of Fazzalari Women's Health at NewYork-Presbyterian The One and Columbia. She is the Richard U. and Ellen J. Levine Assistant Professor of Women's Health (in Obstetrics and Gynecology) at Columbia University Vagelos College of Physicians & Surgeons. She joined the faculty of Obstetrics and Gynecology at Columbia University in April 2018 to provide routine gynecology care and to further develop a comprehensive well-woman program. She has been a practicing obstetrician gynecologist for more than 20 years, starting in private practice and then joining the faculty at Montefiore Medical Center in Bronx, NY. While at Montefiore, she created, launched, and led the forty-person Division of General Obstetrics and Gynecology. Dr. Rosser received her undergraduate degree at Emory University and a Ph.D. in Endocrinology at the Medical College of Georgia. She attended Wake Forest University School of Medicine and completed her residency at Emory University. She is also a NAMS Certified Menopause Practitioner, able to provide high-quality care for patients at menopause and beyond. Primary care and heart disease in women have always been areas of focus for Dr. Rosser. She conducted basic science research on heart disease during graduate school and was the Chair of the "Women & Heart Disease Physician Education Initiative" for District II of the American College of Obstetrics & Gynecology. She continues to conduct clinical studies around patient awareness and understanding of heart disease and well-woman care. Dr. Rosser serves on the Medical Leadership Team of the Go Red for Women movement of the American Heart Association and she is ACOG's liaison to the American College of Cardiology.  

Veja também em youtube.com/@45_graus Ana I. Domingos é neurocientista e Professora de Neurociência na Universidade de Oxford, onde investiga os mecanismos biológicos que regulam o metabolismo e o peso corporal, em particular o papel das redes nervosas simpáticas na queima de gordura e na obesidade. Formou-se em Matemática em Lisboa e Paris e fez o doutoramento na Rockefeller University, em Nova Iorque. O seu trabalho tem sido publicado em revistas científicas de topo como Nature e Cell e distinguido com várias bolsas internacionais, incluindo bolsas do Conselho Europeu de Investigação (ERC). É também membro da EMBO e editora-chefe do American Journal of Physiology – Endocrinology and Metabolism. _______________ Índice (2ª Parte): Porque tem aumentado a obesidade em todo o mundo? Sistema imunitário e obesidade. Imunometabolismo Papel do stress O que explica o nosso peso: genética vs ambiente Estudos com gémeos O caso dos labradores Ozempic: como funciona? Analogia entre obesidade e doenças psiquiátricas Até que ponto a biologia torna fazer dieta impossível para muitas pessoas?See omnystudio.com/listener for privacy information.

Veja também em youtube.com/@45_graus Ana I. Domingos é neurocientista e Professora de Neurociência na Universidade de Oxford, onde investiga os mecanismos biológicos que regulam o metabolismo e o peso corporal, em particular o papel das redes nervosas simpáticas na queima de gordura e na obesidade. Formou-se em Matemática em Lisboa e Paris e fez o doutoramento na Rockefeller University, em Nova Iorque. O seu trabalho tem sido publicado em revistas científicas de topo como Nature e Cell e distinguido com várias bolsas internacionais, incluindo bolsas do Conselho Europeu de Investigação (ERC). É também membro da EMBO e editora-chefe do American Journal of Physiology – Endocrinology and Metabolism. _______________ Índice (1ª parte): Como é definida a obesidade? Limitações do IMC - Índice de Massa Corporal Países do mundo com mais obesidade. Causas genéticas. Leptina O que são calorias? É possível medir calorias que gastamos? Na dieta, é melhor perdermos peso lentamente? Leptina e infertilidade Porque países asiáticos têm baixa obesidade, mas alta incidência de diabetes tipo 2?See omnystudio.com/listener for privacy information.

This episode is a deep dive into the new 2026 guidelines on type 2 diabetes, applying the guidelines to various case-based scenarios. Zero to GP podcast: https://www.buzzsprout.com/2590332Zero to GP YouTube channel: https://www.youtube.com/@ZeroToGPZero to AKT course: https://zerotofinals.com/courses/zerotoakt/Books: https://zerotofinalsshop.com/

Send a textHow the body's internal circadian clocks regulate metabolism, energy balance, and health.TOPICS DISCUSSED:Master circadian clock in the brain: Light detection via retina entrains the suprachiasmatic nucleus, which coordinates body-wide rhythms; intrinsic period slightly deviates from 24 hours, allowing seasonal flexibility.Peripheral clocks in organs: Nearly all cells have autonomous clocks; liver and fat clocks rapidly adjust to feeding time, while brain clock aligns more tightly to light.Clock mutations and metabolism: Disrupting core clock genes (e.g., CLOCK, BMAL1) causes obesity, liver fat accumulation, and impaired insulin secretion without hyperinsulinemia.Timing of food intake: Eating the same high-fat calories during rest phase causes more weight gain than during active phase due to differences in energy dissipation.Modern disruptions (jet lag, shift work, blue light): Create desynchrony between brain and peripheral clocks, contributing to metabolic issues; late-night eating impairs glucose handling.Critical illness & feeding: Tube feeding at night (opposite natural cycle) induces rapid insulin resistance, highlighting mismatch costs.Hormone rhythms: Testosterone, glucocorticoids, and others peak at specific times; misalignment affects stress, reproduction, and metabolism.Weight loss drugs & maintenance: GLP-1 drugs reduce intake effectively, but regain involves neuroendocrine adaptations tied to brain clock pathways.ABOUT THE GUEST: Joseph Bass, MD, PhD is Chief of Endocrinology, Metabolism and Molecular Medicine at Northwestern University Feinberg School of Medicine, Director of the Center for Diabetes and Metabolism, and a leading researcher who pioneered the link between circadian clock genes and metabolic disorders including obesity and diabetes.RELATED EPISODE:M&M 237 | Circadian Biology: Genetics, Behavior, Metabolism, Light, Oxygen & Melatonin | Joseph TakahashiSupport the showHealth Products by M&M Partners: SporesMD: Premium mushrooms products (gourmet mushrooms, nootropics, research). Use code 'nickjikomes' for 20% off. Lumen device: Optimize your metabolism for weight loss or athletic performance. MINDMATTER gets you 15% off. AquaTru: Water filtration devices that remove microplastics, metals, bacteria, and more from your drinking water. Through link, $100 off AquaTru Carafe, Classic & Under Sink Units; $300 off Freestanding models. Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) For all the ways you can support my efforts